Cover Page  for Protocol  
 
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN1436 -4477  
Official title of study:  A [ADDRESS_1232993] and Safety of Once 
Weekly  Insulin Icodec and Once Daily Insulin Glargine 100 
units/mL,  Both in Combination With Non- insulin Anti-
diabetic Treatment, in  Insulin Naïve Subjects With Type 2 
Diabetes (ONWARDS 1)  
Document date:  30-November -2020  
*Document date refers to the date on which the document was most recently updated. 
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
Status:  Final  
Page:  1 of 94 
Protocol
Protocol title: A [ADDRESS_1232994] and safety of once weekly insulin icodec 
and once daily insulin glargine 100 units/mL, both in combination with non-
insulin anti -diabetic treatment, in insulin naïve subjects with type 2 diabetes.  
ONWARDS 1  
Substance: Insulin icodec  
Universal Trial Number: U1111 -[ADDRESS_1232995] Number: 2020 -000442 -34 
IND Number:  137406  
Trial phase: 3a  
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Redacted protocol  
Includes redaction of personal identifiable information only.  
. 
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  2 of 94 
 
Protocol a mendment  summary of changes table  
DOCUMENT HISTORY  
Document version  Date  Applicable in country( -ies) and/or 
site(s)  
Protocol version 4.[ADDRESS_1232996] 2020  [LOCATION_006] only  
Original protocol version 1.0  19 June 2020  All countries  except [LOCATION_006]  and Italy  
 
Protocol version 4.0 (30 November 2020 ) 
This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1, because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
Overall rationale for preparing protocol, version 4.0: 
The protocol has been amended t o allow subjects to co -participate in clinical trials evaluating 
medicinal products for prevention or treatment of COVID -19 disease or postinfectious conditions .   
Section # and name  [CONTACT_111444]  
1.1 Synopsis  Correcting a week numb er. Correction of error  
1.2 Flowchart  Deleted randomisation visit ”X” for 
hypo -reporting .  Correction of error  (hypo-reporting 
should follow AE reporting ). 
2.3.[ADDRESS_1232997].  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  3 of 94 
 
Section # and name  [CONTACT_111444]  
7.[ADDRESS_1232998] 
discontinuation/withdrawal from the  
trial Updated wording to “treatment status 
session”.  Correction of error.  
8.2 Safety assessments  Deleted a sentence  describing a 
disease  specific form in the eCRF . The eCRF for medical history ha s 
change d to include the  diagnosis of 
diabetes, thus the information  is not 
applicable  anymore . 
8.3 Adverse events (AEs) and serious 
adverse events (SAE)  Footnote to table [ADDRESS_1232999] . 
8.9.2 Hypersensitivity  The sentence “ For the subjects 
randomised to insulin icodec” has 
been added in the first paragraph.  To clarify that the additional blood 
sampling is only taken  in the i nsulin 
icodec arm.  
[IP_ADDRESS] Monitoring  Deleted “HCP web portal” and 
“eDiaries”.  Monitors are not requested to perform 
source data verification in the HCP 
web portal.  
10.9 Appendix 9: Country -specific 
requirements  [LOCATION_006] specific BG  meter instruction  
deleted . Specific [LOCATION_006] instruction is not needed.  
10.9 Appendix 9: Country/Region -
specific requirements  Delet ed [LOCATION_003] specific eye 
examination requirement . [LOCATION_003] will follow the global 
requirements for eye examination in 
section 8.2.5 . 
  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  4 of 94 
 
Table of Contents    
 Page  
Protocol a mendment  summary of changes table  ................................ ................................ ...........................  2 
Table of Contents ................................ ................................ ................................ ................................ ..............  4 
1 Protocol summa ry ................................ ................................ ................................ ................................ ..... 8 
1.1 Synopsis  ................................ ................................ ................................ ................................ ...........  8 
1.2 Flowchart  ................................ ................................ ................................ ................................ ....... 11 
1.3 Flowchart – phon e contacts  ................................ ................................ ................................ ...........  14 
2 Introduction  ................................ ................................ ................................ ................................ .............  15 
2.1 Trial rationale  ................................ ................................ ................................ ................................ . 15 
2.2 Background  ................................ ................................ ................................ ................................ .... 15 
2.3 Benefit -risk assessment  ................................ ................................ ................................ ..................  17 
2.3.1  Risk assessment  ................................ ................................ ................................ ...............  17 
2.3.2  Benefit assessment  ................................ ................................ ................................ ...........  20 
2.3.3  Overall benefit -risk conclusion  ................................ ................................ .......................  20 
3 Objectives and endpoints  ................................ ................................ ................................ ........................  21 
3.1 Primary, secondary and exploratory objective and estimand ................................ .........................  21 
3.1.1  Primary objective  ................................ ................................ ................................ .............  21 
3.1.2  Secondary objective  ................................ ................................ ................................ .........  21 
3.1.3  Estimand  ................................ ................................ ................................ ..........................  21 
3.2 Primary, secondary and exploratory endpoints  ................................ ................................ ..............  21 
3.2.1  Primary endpoint  ................................ ................................ ................................ .............  21 
3.2.2  Secondary endpoints  ................................ ................................ ................................ ........  22 
[IP_ADDRESS]  Confirmatory secondary endpoint  ................................ ................................ ... 22 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... [ADDRESS_1233000] yle considerations  ................................ ................................ ................................ .................  28 
5.3.1  Meals and dietary restrictions  ................................ ................................ ..........................  28 
5.3.2  Caffeine, alcohol and tobacco  ................................ ................................ .........................  28 
5.3.3  Physical activity ................................ ................................ ................................ ...............  28 
5.4 Screen failures  ................................ ................................ ................................ ................................  28 
5.5 Run-in criteria, randomisation criteria and dosing day criteria ................................ ......................  28 
6 Treatments  ................................ ................................ ................................ ................................ ...............  28 
6.1 Treatments administered  ................................ ................................ ................................ ................  28 
6.1.1  Medical devices  ................................ ................................ ................................ ...............  30 
[IP_ADDRESS]  Investigational medical device  ................................ ................................ ........  30 
[IP_ADDRESS]  Non-investigational medical devices  ................................ ..............................  30 
6.2 Preparation/handling/storage/accountability  ................................ ................................ ..................  30 
6.3 Measures to minimise bias: Randomisation and blinding  ................................ .............................  31 
6.4 Treatment compliance  ................................ ................................ ................................ ....................  31 
6.5 Concomitant medication  ................................ ................................ ................................ ................  32 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233001] discontinuation/withdrawal  ................................ ..... [ADDRESS_1233002] discontinuation/withdrawal from the trial  ................................ ................................ .........  [ADDRESS_1233003] to follow -up ................................ ................................ ................................ ...........................  35 
8 Trial asse ssments and procedures  ................................ ................................ ................................ .........  35 
8.1 Efficacy assessments  ................................ ................................ ................................ ......................  36 
8.1.1  Self-measured plasma glucose (SMPG)  ................................ ................................ ..........  37 
8.1.2  Continuous glucose monitoring (CGM)  ................................ ................................ ..........  37 
8.1.3  Clinical efficacy laboratory assessments  ................................ ................................ .........  38 
8.2 Safety assessments  ................................ ................................ ................................ .........................  38 
8.2.1  Insulin dose  ................................ ................................ ................................ ......................  38 
8.2.2  Physical  examinations  ................................ ................................ ................................ ..... 39 
8.2.3  Vital signs  ................................ ................................ ................................ ........................  39 
8.2.4  Electrocardiograms  ................................ ................................ ................................ ..........  40 
8.2.5  Eye examination  ................................ ................................ ................................ ..............  40 
8.2.6  Clinical safety laboratory assessments  ................................ ................................ ............  41 
8.3 Adverse events (AEs) and serious adverse events (SAE)  ................................ ..............................  41 
8.3.1  Time period and frequency for collecting AE and SAE information  ..............................  42 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ................  43 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ...........................  43 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ................................ .. 43 
8.3.5  Pregnancy  ................................ ................................ ................................ ........................  43 
8.3.6  Cardiovascular and death events  ................................ ................................ .....................  44 
8.3.7  Disease -related events and/or disease -related outcomes not qualifying as an AE or 
SAE  ................................ ................................ ................................ ................................ . 44 
8.3.8  Adverse event of special interesta ................................ ................................ ....................  44 
8.3.9  Technical complaints  ................................ ................................ ................................ ....... 44 
8.4 Treatment of overdose  ................................ ................................ ................................ ...................  44 
8.5 Pharmacokinetics  ................................ ................................ ................................ ...........................  45 
8.6 Pharmacodynamics  ................................ ................................ ................................ ........................  45 
8.7 Genetics  ................................ ................................ ................................ ................................ .........  45 
8.8 Biomarkers  ................................ ................................ ................................ ................................ ..... 45 
8.9 Immunogenicity  assessments  ................................ ................................ ................................ .........  45 
8.9.1  Anti-drug antibodies  ................................ ................................ ................................ ........  45 
8.9.2  Hypersensitivity  ................................ ................................ ................................ ...............  45 
8.10  Healt h economics  ................................ ................................ ................................ ...........................  46 
9 Statistical considerations  ................................ ................................ ................................ ........................  46 
9.1 Statistical hypotheses  ................................ ................................ ................................ .....................  46 
9.2 Sample size determination  ................................ ................................ ................................ .............  47 
9.3 Populations for analyses  ................................ ................................ ................................ ................  48 
9.4 Statistical analyses  ................................ ................................ ................................ .........................  49 
9.4.1  General considerations  ................................ ................................ ................................ .... 49 
9.4.2  Primary endpoint  ................................ ................................ ................................ .............  50 
9.4.3  Seco ndary endpoints  ................................ ................................ ................................ ........  51 
[IP_ADDRESS]  Confirmatory secondary endpoint  ................................ ................................ ... 51 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... 51 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  6 of 94 
 
9.4.4  Exploratory endpoints  ................................ ................................ ................................ ..... 53 
9.4.5  Other safety analyses  ................................ ................................ ................................ ....... 53 
9.4.6  Other analyses  ................................ ................................ ................................ .................  53 
[IP_ADDRESS]  Pharmacokinetic modelling  ................................ ................................ .............  53 
9.5 Interim analyses  ................................ ................................ ................................ .............................  53 
9.6 Data mon itoring committee  ................................ ................................ ................................ ...........  54 
9.7 Reporting of the main phase of the trial  ................................ ................................ .........................  54 
10 Supporting documentation and operational considerations  ................................ ...............................  55 
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations  ................................ .............  55 
10.1.1  Regulatory and ethical considerations  ................................ ................................ .............  55 
10.1.2  Financial disclosure  ................................ ................................ ................................ .........  55 
10.1.3  Informed consent process  ................................ ................................ ................................  55 
10.1.4  Information to subjects during trial  ................................ ................................ .................  56 
10.1.5  Data protection  ................................ ................................ ................................ ................  56 
10.1.6  Committees structure  ................................ ................................ ................................ ....... 57 
10.1.6 .1 Novo Nordisk safety committee ................................ ................................ ...... 57 
[IP_ADDRESS]  Trial safety group  ................................ ................................ ............................  57 
[IP_ADDRESS]  Data monitoring committee ................................ ................................ .............  57 
[IP_ADDRESS]  Event adjudication committee  ................................ ................................ .........  57 
10.1.7  Dissemination of clinical trial data  ................................ ................................ ..................  57 
10.1.8  Data quality assurance  ................................ ................................ ................................ ..... 57 
[IP_ADDRESS]  Case report forms  ................................ ................................ ............................  57 
[IP_ADDRESS]  Monitoring  ................................ ................................ ................................ ...... 58 
[IP_ADDRESS]  Proto col compliance  ................................ ................................ ........................  59 
10.1.9  Source documents  ................................ ................................ ................................ ............  59 
10.1.10  Retention of clinical trial documentation  ................................ ................................ ........  59 
10.1.11  Trial and site closure  ................................ ................................ ................................ ....... 60 
10.1.12  Responsibilities ................................ ................................ ................................ ................  60 
10.1.13  Indemnity statement  ................................ ................................ ................................ ........  61 
10.1.14  Publication policy  ................................ ................................ ................................ ............  61 
[IP_ADDRESS]  Communication of results  ................................ ................................ ...............  61 
[IP_ADDRESS]  Authorship  ................................ ................................ ................................ ....... 62 
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s) ................................ .................  62 
[IP_ADDRESS]  Investigator access to data and review of results  ................................ ............  62 
10.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ............................  63 
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow -
up, and reporting  ................................ ................................ ................................ ............................  65 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............  65 
10.3.2  Definition of an SAE  ................................ ................................ ................................ ....... 65 
10.3.3  Description of event(s) for adjudication and AEs requiring additional data 
collection  ................................ ................................ ................................ .........................  66 
10.3.4  Recording and follow -up of AE and/or SAE  ................................ ................................ ... 68 
10.3.5  Reporting of SAEs  ................................ ................................ ................................ ...........  70 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  ............................  72 
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow -up and reporting  ................................ ................................ ................................ .................  75 
10.5.1  Definition of technical complaint  ................................ ................................ ....................  75 
10.5.2  Recording and follow -up of technical complaints  ................................ ...........................  75 
10.5.3  Reporting of technical complaints  ................................ ................................ ...................  76 
10.6  Appendix 6: Retention of human biosamples  ................................ ................................ ................  77 
10.7  Appendix 7: Hypoglycaemic epi[INVESTIGATOR_1841]  ................................ ................................ ...........................  78 
10.8  Appendix 8: Titration guideline  ................................ ................................ ................................ ..... 80 
10.9  Appendix 9: Country -specific requirements  ................................ ................................ ..................  83 
10.10  Appendix 10: Abbreviations  ................................ ................................ ................................ ..........  87 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  7 of 94 
 
10.11  Appendix 11: Protocol amendment history  ................................ ................................ ...................  [ADDRESS_1233004] of key staff and relevant departments . 
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  8 of 94 
 
1 Protocol summary  
1.1 Synopsis  
Rationale:  
Insulin icodec is a novel long -acting insulin analogue which is developed to safely cover the basal 
insulin requirements for a full week with a single subcutaneous injection.  
The present trial is designed to investigate  the effect and long -term safety of once weekly insulin 
icodec in comparison to once daily insulin glargine  100 units/mL  (referred to as insulin glargine in 
this document) , both in combination with non -insulin anti -diabetic drugs in insulin naïve subjects 
with type 2 diabetes ( T2D). The effect of insulin icodec is evaluated after a 52 -week main phase, 
followed by a 26 -week extension p hase with the primary aim to assess long -term safety.  
Objectives and endpoints:  
Primary objective  
The objective of this trial is  to demonstrate the effect on glycaemic control of once weekly insulin 
icodec, in combination with non -insulin anti -diabetic drugs, in insulin naïve subjects with T2D. 
This includes comparing the difference in change from baseline in HbA 1c between insulin icodec 
and insulin glargine after 52 weeks of treatment to a non -inferiority limit of 0.3% . 
Key secondary objective  
To compar e parameters of glycaemic control and safety of once weekly insulin icodec with once 
daily insulin glargine, both in combination with non -insulin anti -diabetic drugs, in insulin naïve 
subjects with T2D.  
Estimand  
The estimand is the  ‘treatment policy estimand’  defined as the treatment difference between insulin 
icodec and insulin  glargine  of the change in HbA 1c from baseline to week  52 for all randomised 
subjects, irrespective of adherence to randomised treatment and changes to anti -diabetic background  
medication. The following intercurrent events will be handled by [CONTACT_17983]: 
Initiation of bolus insulin treatment for more than 2 weeks , discontinuation of randomised insulin 
treatment, and withdrawal from the trial (measurements colle cted after these intercurrent events are 
used in the primary analysis).  
Primary endpoint  
Endpoint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 52 
(V46)  %-point  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  9 of 94 
 
Confirmatory secondary endpoint  
Endpoint title  Time frame  Unit  
Time in target range 3.9 -10.0 mmol/L 
(70-180 mg/dL)*  From week 48 (V42) to week 52 (V46)  % of readings  
* using continuous glucose monitoring (CGM) system, Dexcom G6  
Overall design:  
This is a 78-week randomised, open label, active -controlled, parallel -group, multicentre, 
multinational, treat -to-target trial with two treatment arms.  
The first 52 weeks of the trial constitute the main phase, after which the primary and confirmatory 
secondary endpo ints are analysed. The focus of the 26 weeks extension phase is to evaluate long 
term safety. However, all endpoints will be analysed for the main phase and for the entire trial 
which includes both the main and the extension phase.  
Subjects will be random ised (1:1) to receive once weekly insulin icodec or once daily insulin 
glargine.  
Continuous glucose monitoring  (CGM ) profiles will be collected  to evaluate the effect on 
glycaemic control. The CGM receiver will be blinded for both subjects and investigators.  
Key inclusion criteria : 
1. Male or female aged above or equal to 18 years at the time of signing informed consent .  
2. Diagnosed with T2D ≥ 180 days prior to the day of screening.  
3. HbA 1c from 7.0 -11.0% (53.0 -96.7 mmol/mol) both inclusive at screeni ng confirmed by [CONTACT_111392].  
4. Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day 
of screening is allowed, as is prior insulin treatment for gestational diabetes.  
5. Stable daily dose(s) ≥ 90 days prio r to the day of screening of any of the following anti -diabetic 
drug(s) or combination regimen(s):  
a. Any metformin formulations ≥ 1500 mg or maximum tolerated or effective dose.  
b. Any metformin combination formulations ≥ 1500 mg or maximum tolerated or effective 
dose.  
c. Any of the following oral anti -diabetic drug classes including combinations (≥ half of the 
maximum approved dose according to local label or maximum tolerated or effective 
dose): 
• Sulfonylureas  
• Meglitinides (glinides)  
• DPP-4 inhibitors  
• SGLT2 inhibitors  
• Thiazolidinediones  
• Alpha -glucosidase inhibitors  
• Oral combination products (for the allowed individual oral anti-diabetic drugs)  
• Oral or injectable GLP -1 receptor agonists   
6. Body  mass index (BMI) ≤ 40.0 kg/m2. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  10 of 94 
 
Key exclusion criteria : 
1. Any epi[INVESTIGATOR_111342] 90 days prior to the day of screening.  
2. Myocardial infarction, stroke, hospi[INVESTIGATOR_41070] 180 days prior to the day of screening.  
3. Chronic heart failure classifie d as being in [LOCATION_001] Heart Association Class IV at screening.  
4. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or  
corticosteroids).  
5. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus 
examination performed within the past [ADDRESS_1233005] or in the medical records.  
Number of subjects:  
Approximately [ADDRESS_1233006].  
Treatment groups and duration:  
The trial duration is approximately [ADDRESS_1233007] s will be 
centrally randomised in a 1:[ADDRESS_1233008] at the discr etion of the investigator.   
The following trial products will be supplied by [CONTACT_111393]:  
• Insulin icodec 700 units/mL, subcutaneous , solution for injection, 3 mL PDS290 pre -filled 
pen-injector  
• Insulin glargine 100 units/mL, subcutaneous , solution for injection , 3 mL SoloSTAR pre -filled 
pen-injector.  
Data monitoring committee: No  
CONFIDENTIAL
Protocol        Date:  30 November 2020  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4477        Version:  4.0 Page:  [ADDRESS_1233009] 
number (P) (For 
details see separate 
flow chart in 1.3)       P7 
  P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23     P29 P31 
P32 
P33  
P35   
P37   
P39   
P41        
P48   
P50   
P52   
P54   
 P56          
 
Timing of visit 
(weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 32 36 40 44 48 49 50 51 52 54 58 62 66 70 74 75 76 77 78 80 83 52 78 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3 
Informed consent 
and demography  10.1 
App. 
1 X                                      
 
Tobacco use  5.3.2  X                                       
Eligibility criteria  5.1 
5.2 X X                                      
Attend visit fasting  5.3.1   X      X  X     X          X          X     
Concomitant 
illness/medical 
history  8.2 X X                                     
 
Concomitant 
medication  6.5 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Vital signs  8.2.3  X        X      X          X          X     
Physical 
examination  8.2.2  X                        X          X     
Body measurements  8.2.2  X X       X      X          X          X   X X 
CONFIDENTIAL
Protocol        Date:  30 November 2020  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4477        Version:  4.0 Page:  [ADDRESS_1233010] 
number (P) (For 
details see separate 
flow chart in 1.3)       P7 
  P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23     P29 P31 
P32 
P33  
P35   
P37   
P39   
P41        
P48   
P50   
P52   
P54   
 P56          
 
Timing of visit 
(weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 32 36 40 44 48 49 50 51 52 54 58 62 66 70 74 75 76 77 78 80 83 52 78 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1233011]  8.3.5  
10.4 
App. 4  X                       X          X  X  
 
Laboratory 
assessments  10.2 
App.2  X X      X  X     X   X  X     X   X  X     X   X X 
HbA1c   X X      X  X     X   X  X     X   X  X     X   X X 
Self-measured 
plasma glucose  8.1.1   X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X   
CGM  8.1.2   X X X X X     X X X X X      X X X X X      X X X X X X X   
Adverse event  8.3 
10.3 
App. 
3   X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Hypoglycaemic 
epi[INVESTIGATOR_1841]  8.3 
10.7 
App. 
7   X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X  
 
CONFIDENTIAL
Protocol        Date:  30 November 2020  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4477        Version:  4.0 Page:  [ADDRESS_1233012] 
number (P) (For 
details see separate 
flow chart in 1.3)       P7 
  P9 
P10 
P11 P13 
P14 
P15 P17 
P18 
P19 P21 
P22 
P23     P29 P31 
P32 
P33  
P35   
P37   
P39   
P41        
P48   
P50   
P52   
P54   
 P56          
 
Timing of visit 
(weeks)   ≤-2 0 1 2 3 4 6 10 14 18 22 23 24 25 26 28 32 36 40 44 48 49 50 51 52 54 58 62 66 70 74 75 76 77 78 80 83 52 78 
Visit window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_1233013] in devices  6  X                                      
End of Trial  4.4                                     X  X 
CONFIDENTIAL
Protocol        Date:  30 November 2020  Status:  Final  Novo Nordisk  
Trial ID: NN1436 -4477        Version:  4.0 Page:  14 of 94 
 
1.3 Flowchart – phone contacts  
Procedure  Protocol section  Treatment  
Visit   P7 P9 P10 P11 P13 P14 P15 P17 P18 P19 P21 P22 P23 P29 P31 P32 P33 P35 P37 P39 P41 P48 P50 P52 P54 P56 
Timing of visit 
(weeks)   5 7 8 9 11 12 13 15 16 17 19 20 21 27 29 30 31 34 38 42 46 56 60 64 68 72 
Visit window 
(days)   ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 
Concomitant 
medication  6.5 X X X X X X X X X X X X X X X X X X X X X X X X X X 
Self-measured 
plasma glucose  8.1.1  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Adverse events  8.3 10.3 
App. 3  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Hypoglycaemic 
epi[INVESTIGATOR_1841]  8.3 10.7 
App. 7  X X X X X X X X X X X X X X X X X X X X X X X X X X 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  15 of 94 
 
2 Introduction  
Diabetes mellitus is a metabolic disorder characterised by [CONTACT_41125], insulin action or both. The chronic hyperglycaemia of diabetes mellitus 
is associated with significant long -term complications, particularly damage, dysfunction and failure 
of various tissues – especially the kidney, eye, nerves, heart and blood vessels .2 Diabetes is 
generally classified according to aetiological factors, where type 1 diabetes (T1D) and type 2 
diabetes (T2D) constitute the vast majority of cases. In the latest edition of the International 
Diabetes Federation’s Diabe tes Atlas (2019), the estimated worldwide diabetes prevalence was [ADDRESS_1233014] increased to 
700 million.3 
Insulin icodec (proposed INN) is a novel long -acting insulin analogue which is developed to safely 
cover the basal insulin requirements for a full week with a single subcutaneous injec tion. Insulin 
icodec has a terminal elimination half -life of approximately [ADDRESS_1233015] and long -term safety of once weekly insulin 
icodec in comparison to once daily insulin glargine 100 units/mL (referred to as insulin glargine in 
this document), both in combination with non -insulin anti -diabetic drugs in insulin naïve subjects 
with T2D. The effect of insulin icodec is evaluated after the [ADDRESS_1233016] and long -term safety 
parameters of insulin icodec in insulin naïve T2D subjects and will support the marketing 
authorisation approval of insulin icodec. The trial will also generate data on dosing flexibility.  
2.2 Background  
Diabetes mellitus  
T2D is characterised by [CONTACT_30361], impaired insulin secretion, increased hepatic glucose 
output due to glucagon dysregulation resulting in chronic hyperglycaemia.5 The pathogenesis is not 
fully understood but seems to be heterogeneous, involving environmental, lifestyle, and genetic 
factors leading to chronic hyperglycaemia caused by [CONTACT_111394], impaired 
insulin secretion due to abnormal be ta-cell function and abnormal glucose metabolism in the liver.6 
The current treatment cascade follows a stepwise approach comprising lifestyle changes in 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  16 of 94 
 
combination with pharmac ological intervention. In many countries, metformin is recommended as 
initial pharmacological therapy, followed by [CONTACT_111395] -diabetic 
drugs, glucagon -like peptide 1 receptor agonists (GLP -1 RA) and/or insulin as the disease 
progresses.7 On average, after failure of diet and exercise alone, subjects  require a new intervention 
with glucose -lowering agents every 3 -4 years in order to obtain/retain good glycaemic control.8 
Clinical inertia, often resulting from a resistance to insulin initiation and intensification, is a major 
contributing factor to subjects  with T2D who are not achieving recommended glycaemic targets.9, 10 
Increased convenience is believed to support timely insulin initiation in the treatment for T2D and 
thereby [CONTACT_881855].  
Insulin icodec  
Insulin icodec is a novel long -acting insulin analogue which is developed to safely cover the basal 
insulin requirements for a full week with a single subcutaneous  injection. Insulin icodec has a 
terminal eliminati on half -life of approximately 196 hours. The molecule consists of a peptide 
backbone and a fatty acid -containing side -chain. The peptide backbone is more resistant towards 
proteolytical degradation compared to human insulin and the side chain gives a stron g binding to 
albumin. Both features contribute to the long action of insulin icodec.  
The development programme for insulin icodec is currently ongoing. Three clinical pharmacology 
trials, NN1436 -4314 [T2D], NN1436 -4226 [renal impaired] and NN1436 -4422 [T1 D] have been 
completed. No unexpected  safety concerns were identified. Two clinical pharmacology trials 
(NN1436 -4462 [T2D] and NN1436 -4225 [T1D]) are ongoing.  
Three phase [ADDRESS_1233017] recently been completed (NN1436 -4465, NN1436 -
4383 and NN1436 -4466). Once weekly insulin icodec was shown to provide comparable glucose 
lowering effects and similar safety profile to insulin glargine in subjects with T2D. Results from 
these trials were used in the development of the insulin icodec titratio n guideline, see Appendix 8  
(Section 10.8).   
A comprehensive review of results from the non -clinical and clinical studies of insulin icodec can 
be found in the current edition of the investigator’s brochure11 and any updates hereof.  
Insulin glargine  
For further details on insulin glargine, please refer to the current EMA summary of product 
characteristics for insulin glargine (Lantus®)12, the US prescribing information  for insulin glargine 
(Lantus®)13, or any locally approved label.  
Trial population  
The trial population will consist of insulin naïve subjects with T2D.  
This population has been chosen to ensure that a broad T2D subject  group is represented across the 
clinical development programme.  
Subjects with T1D are excluded from this t rial. Subjects with T1D will be addressed in a dedicated 
trial. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233018] the 
possibility of a causal relationship with insulin icodec, but where t here is currently insufficient 
evidence to conclude that this association is causal.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  18 of 94 
 
Identified/Potential risk of clinical 
significance  
 Summary of data/rationale for 
risk 
 Mitigation strategy   
Trial treatment: insulin icodec  
Identified risk:  
Hypoglycemia  Hypoglycemia is an anticipated 
undesirable effect related to the 
pharmacological mechanism of 
insulin . Frequent blood glucose 
measurements will be made 
throughout drug exposure and will 
prevent worsening of hypoglycaemia 
by [CONTACT_881856], if necessary.  
The risk of hypoglycaemia is 
addressed in the SI -IC and IB11. 
Subject s are provided with a 
guidance on hypoglycaemia 
awareness and rescue actions.  
Identified risk: Injection site 
reactions  Injection site reactions may occur 
with all injectable drugs. Injection 
site reactions were reported in trials 
NN1436 -4422, NN1436 -4383, 
NN1436 -4465, NN1436 -4466, 
NN1436 -4226. All were mild and 
resolved during continued treatment 
with insulin icodec.  Subjects are in structed by [CONTACT_881857].  
Recommendations on rotation of the 
site of injection are included in the 
trial protocol and SI -IC.  
Investigators and subjects will be 
instructed to monitor for injection 
site rea ctions at the place of injection 
for early detection. Investigators 
should ensure careful monitoring 
and medical evaluation in case of 
injection site reaction occurrence. 
The risk of injection site reactions is 
described in the IB11 and the SI -IC. 
For further information on i njection 
site reactions, please refer to section 
8.9.2  and Appendix 3  (Section 
10.3.3 ). 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  19 of 94 
 
Potential risk:  
Hypersensitivity  Severe systemic hypersensitivity 
reactions may potentially occur 
following injection of therapeutic 
proteins. No systemic 
hypersensitivity reactions were 
observed in trials NN1436 -4314, 
NN1436 -4383, NN1436 -4465, 
NN1436 -4466, NN1436 -[ADDRESS_1233019](s) or related products 
is an exclusion criterion in the 
clinical trial.  
Subjects and investigators will be 
instructed in signs and symptoms of 
hypersensitivity reactions and 
subje cts will be instructed to contact 
[CONTACT_881858].  
Blood sampling for assessment of 
antibodies against insulin icodec, as 
well as other assessments will be 
conducted in the case of systemic 
hypersensitivit y reaction. Confirmed 
anti-insulin icodec antibody positive 
samples will have an antibody titer 
value determined and will be further 
tested for cross -reactivity to 
endogenous insulin.  
The risk of hypersensitivity reactions 
is described in the IB11 and SI -IC.   
For further information on 
hypersensitivity reactions, please 
refer to Section s 8.9.2  and 10.3.3 . 
Potential risks:  
Antibody formation leading to 
changes in clinical effect  Antibodies to exogenously delivered 
insulin are common with insulin 
treatment but are not often clinically 
significant.  
In trial NN1436 -4383, the proportion 
of subjects with anti -insulin 
antibodies was higher with insulin 
icodec (82.1%) than insulin glargine 
(35.0%).  
Maximum level of antibody response 
was higher against insulin icodec 
than insulin glargine.  
No apparent relationship between 
antibody titres and change in HbA 1c 
or weekly insulin dose was observed.   In the case of systemic 
hypersensitivity reaction blood 
sampling for assessment of 
antibodies against insulin icodec, as 
well as other assessments wil l be 
conducted. For more information, 
please refer to Section s 8.9.2  and 
10.3.3 . 
Trial procedures  
Potential risk: COVID -[ADDRESS_1233020] been taken:  
• Cautious subject  recruitment 
planning ensures controlled 
subject  enrolment in countries 
where the COVID -19 pande mic 
is evaluated to be sufficiently 
under control, and at sites 
where health care resources are 
evaluated to be adequate . 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  20 of 94 
 
• On-site visits will be well -
prepared and as short as 
possible. Physical contact 
[CONTACT_111401] s and site staff 
will be limited to the  extent 
possible, and protective 
measures will be implemented 
(e.g. use of masks, sanitizers, 
no aerosol -generating 
procedures etc. according to the 
local practice) . 
• A COVID -[ADDRESS_1233021] of insulin naïve subjects with T2D. For all subjects participating in 
this 78 -week trial, the anticipated benefits include improved glycaemic control. The titration 
algorithm in Appendix  8 (Section 10.8), which specifies recommended adjustments of basal insulin 
dose at different plasma glucose levels, will be used to ensure tha t subjects receive optimal 
treatment. Subjects will receive intense medical care by [CONTACT_881859].  
2.3.3 Overall benefit -risk conclusion  
Insulin icodec is efficacious at clinically relevant doses. Titration guidance f or phase 3a trials aims 
to achieve good glycaemic control without increasing the risk of hypoglycaemic events.  
No new significant safety information that changes the current benefit –risk profile of insulin icodec 
emerged from the ongoing and completed cli nical trials. The safety profile of insulin icodec remains 
in line with the cumulative experience.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  21 of 94 
 
As an overall assessment, Novo Nordisk evaluates that the benefit –risk balance of insulin icodec 
remains favourable.  
Considering the measures taken to minimise risk to subjects participating in this trial, the potential 
risks identified in association with insulin icodec are justified by [CONTACT_111403] . 
More detailed information about the known and expected benefits and risk of insulin icodec can be 
found in the investigator’s brochure11 and any updates hereof.  
[ADDRESS_1233022] on glycaemic control of  once weekly insulin icodec, in combination with 
non-insulin anti -diabetic drugs, in insulin naïve subjects with T2D. This includes comparing the 
difference in change from baseline in HbA 1c between insulin icodec and insulin glargine after 52 
weeks of trea tment to a non -inferiority limit of 0.3%.  
3.1.2 Secondary objective  
To compare parameters of glycaemic control and safety of once weekly insulin icodec with once 
daily insulin glargine, both in combination with non -insulin anti -diabetic drugs, in insulin naïve 
subjects with T2D.  
3.1.3 Estimand  
The estimand is the ‘treatment policy estimand’ defined as the treatment difference between insulin 
icodec and insulin glargine of the change in HbA 1c from baseline to week 52 for all randomised 
subjects, irrespective of adherence to randomised treatment and changes to anti -diabetic background 
medication. The following intercurrent events will be handled by [CONTACT_17983]: 
Initiation of bolus insulin treatment for  more than 2 weeks, discontinuation of randomised insulin 
treatment, and withdrawal from the trial (measurements collected after these intercurrent events are 
used in the primary analysis).  
3.2 Primary, secondary and exploratory endpoints  
3.2.1 Primary endpoint  
Endp oint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 52 (V46)  %-point  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  22 of 94 
 
3.2.2 Secondary endpoints  
[IP_ADDRESS]  Confirmatory secondary endpoint  
Endpoint title  Time frame  Unit  
Time in target range 3.9 -10.0 mmol/L 
(70-180 mg/dL)*  From week 48 (V42) to week 52 (V46)  % of readings  
* using continuous glucose monitoring (CGM) system, Dexcom G6  
 
[IP_ADDRESS]  Supportive secondary endpoints  
Secondary efficacy endpoint  
Endpoint title  Time frame  Unit  
Change in fasting plasma glucose (FPG)  From baseline week 0 (V2) to week 52 (V46)  mmol/L  
 
Secondary safety endpoints   
Endpoint title  Time frame  Unit  
Number of severe hypoglycaemic 
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 52 (V46)  Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0  mmol/L  (54 mg/dL) confirmed by 
[CONTACT_41132])  From baseline week 0 (V2) to week 52 (V46)  Number of epi[INVESTIGATOR_111345] (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed by [CONTACT_339692])  or severe hypoglycaemic epi[INVESTIGATOR_1841] 
(level 3)  From baseline week 0 (V2) to week 52 (V46)  Number of epi[INVESTIGATOR_463399] (level 3)  From baseline week 0 (V2) to week 83 (V63)  Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0  mmol/L  (54 mg/dL) confirmed by 
[CONTACT_41132])  From baseline week 0 (V2) to week 83 (V63)  Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0  mmol/L  (54 mg/dL), confirmed by 
[CONTACT_41132]) or  severe hypoglycaemic 
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 83 (V63)  Number of epi[INVESTIGATOR_881840] 50 (V44) to week 52 (V46)  U 
Change in body weight  From baseline week 0 (V2) to week 52 (V46)  kg 
Time spent < 3.0 mmol/L (54 mg/dL)*  From week 48 (V42) to week 52 (V46)  % of readings  
Time spent > 10 mmol/L (180 mg/dL)*  From week 48 (V42) to week 52 (V46)  % of readings  
* using continuous glucose monitoring (CGM) system, Dexcom G6  
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  23 of 94 
 
3.2.3 Exploratory endpoints  
Endpoint title  Time frame  Unit  
Number of severe hypoglycaemic  
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 78 (V61) Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0  mmol/L  (54 mg/dL), confirmed by 
[CONTACT_41132])  From baseline week 0 (V2) to week 78 (V61) Number of epi[INVESTIGATOR_111345] (level 2) 
(<3.0  mmol/L  (54 mg/dL), confirmed by 
[CONTACT_41132]) or severe hypoglycaemic 
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 78 (V61) Number of epi[INVESTIGATOR_1841]  
 
[ADDRESS_1233023] 52 weeks of the 
trial constitute the main phase, after which the primary and confirmatory secondary  endpoints are 
analysed. The focus of the 26 weeks extension phase is to evaluate long term safety. However, all 
endpoints will be analysed for the main phase and for the entire trial including  both the main and  
the extension phase.  
The overall trial design and visit schedule are out lined in Figure  4-1 and trial flowchart (see 
Section  1.2), respectively.  
 
 
Figure  4-1 Trial design  
Subjects will be randomised (1:1) to receive once weekly insulin icodec or once daily insulin 
glargine. The dose and dosing frequency of any pre -trial non -insulin anti -diabetic treatment should 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  24 of 94 
 
not be changed during the trial unless due to safety concerns; except for tr eatment with 
sulfonylureas and glinides that must be discontinued at randomisation. During the 78-week 
treatment period, subjects will have contact [CONTACT_881860]. The end of treatment visit (V 61) will be one week after the last dose of insulin 
icodec and on the day of or the day after the last dose of insulin glargine. Two follow -up visits ( V62 
and V63) will be performed [ADDRESS_1233024] continuous glucose monitoring  
(CGM ) profiles collected, as specified in the flowchart (see Section 1.2). The CGM data will be 
blinded for both subjects and investigators.  
Event adjudication will be performed for acute coronary syndrome events (acute myocardial 
infarction or unstable angina pectoris requiring hospi[INVESTIGATOR_11956]), cerebrovascular events (stroke or 
transient ischemic a ttack), heart failure (requiring hospi[INVESTIGATOR_111347]) and 
all-cause death.  
4.[ADDRESS_1233025] on glycaemic control and safety of once weekly insulin 
icodec versus once daily insulin glargine during 78 weeks of treatment. The trial duration and 
number of subjects were chosen to accommodate regulatory requirements for long -term insulin 
icodec exposure for safety evaluation.  
Currently, basal insulins are dosed once or twice daily. In order to compare to well established and 
widely used basal insulin analogues with once daily dosing, insulin glargine has been chosen as 
comparator.  
The treatment arms will be open label as it was not considered feasible to blind the two tr eatments 
since it would increase the burden on the subjects, due to the high number of injections required for 
a double -blind, double dummy trial.  
The treat -to-target approach serves to ensure optimal titration of insulin to improve HbA 1c. Insulin 
titratio n will be based on self -measured plasma glucose (SMPG) values.  
Titration of insulin icodec and insulin glargine will be based on pre -breakfast SMPG values and 
follow the principles outlined in the titration guideline, see Appendix 8  (Section 10.8). CGM values 
will be used during the reporting phase to generate profiles for evaluating the effect on glycaemic 
control during initiation of trial product, steady state and follow -up. To avoid influence on titration 
and the glycaemic control the CGM data will be blinded for both subjects and investigator . 
The trial population will be restricted to insulin naïve subj ects on current treatment with non -
insulin , anti-diabetic drugs. This population was chosen to ensure representativeness for a broad 
type [ADDRESS_1233026]  group. Pre -trial treatment with all non -insulin anti -diabetic drugs is allowed, 
however, to decreas e the risk of hypoglycaemia, sulfonylureas and glinides will be discontinued at 
randomisation.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233027] and safety of once weekly insulin icodec. The HbA 1c limits of 7.0 -11.0% (53.0 -
96.7 mmol/mol) have been chose n to include subjects needing intensification of their anti -diabetic 
treatment.  
During the [ADDRESS_1233028] will be 
weekly including two CGM collection periods. From week 32 (V34) to end of treatment (V61), 
visits will be every other week except for weekly contact [CONTACT_881861] 
48 (V42) to week 52 (V46) and from week 74 (V57) to en d of treatment week 78 (V61). The end of 
trial visit is planned six weeks after the last weekly dose of insulin icodec, allowing enough time for 
wash -out of trial drug, following at least five half -lives of insulin icodec.  
A sufficient assay -sensitivity fo r the non -inferiority evaluation will be ensured by [CONTACT_111243] -to-target 
trial design, the applied titration target/algorithm together with close titration surveillance and by 
[CONTACT_111404].  
4.2.[ADDRESS_1233029] to one unit of insulin 
glarg ine, and therefore once weekly dosing corresponds to seven times the daily dose of the once 
daily comparator.  
The PK/PD properties of insulin icodec following five weeks of once weekly dosing in subjects 
with T2D (trial NN1436 -4314) showed that insulin ic odec exposure was well distributed across the 
dosing interval, with a PK profile suitable for once weekly dosing. Insulin icodec was well tolerated 
in subjects with T2D and no unexpected  safety concerns were identified after multiple once weekly 
dosing in the dose range of 12−24 nmol/kg (2 -4 units/Kg).  
After random isation, subjects should start once daily insulin glargine or once weekly insulin icodec 
injections on the same day. Due to th e longer half -life of insulin icodec, t he last dose of insulin 
icodec will be administered [ADDRESS_1233030] dose of once daily insulin 
glargine will be administered  78 weeks a fter randomisation.  The follow -up period  for both ins ulin 
icodec and insulin glargine will be  the 5 weeks from  end of treatment (V 61) until end of trial (V 63). 
Further details on dose adjustment can be found in the titration guideline in 
Appendix  8 (Section  10.8). 
4.[ADDRESS_1233031] completed the trial if he/she has completed all phases of the trial 
including the last visit.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233032] in the trial globally . 
5 Trial population  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
For country -specific requirement to the inclusion and exclusion  criteria, please refer to Appendix 9  
(Section 10.9) for further information . 
5.1 Inclusion criteria  
Subjects are eligible to be included in the trial only if all the following criteria apply:  
1. Informed consent obtained before any trial -related activities. Trial -related activities are any  
procedures that are carried out as part of the trial, including activities to determine suitability for  
the trial.  
2. Male or female.  
3. Age above or equal to 18 years at the time of signing informed consent.  
4. Diagnosed with T2D ≥ 180 days prior to the day of screening.  
5. HbA 1c from 7.0 -11.0% (53.0 -96.7 mmol/mol) both inclusive at screening confirmed by [CONTACT_111392].  
6. Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day 
of screening is allowed, as is prior insulin treatment  for gestational diabetes.  
7. Stable daily dose(s) ≥ 90 days prior to the day of screening of any of the following anti -diabetic 
drug(s) or combination regimen(s):  
a. Any metformin formulations ≥ 1500 mg or maximum tolerated or effective dose.  
b. Any metformin comb ination formulations ≥ 1500 mg or maximum tolerated or effective 
dose.  
c. Any of the following oral anti -diabetic drug classes including combinations (≥ half of the 
maximum approved dose according to local label or maximum tolerated or effective 
dose):  
• Sulfon ylureas  
• Meglitinides (glinides)  
• DPP-4 inhibitors  
• SGLT2 inhibitors  
• Thiazolidinediones  
• Alpha -glucosidase inhibitors  
• Oral combination products (for the allowed individual oral anti-diabetic drugs)  
• Oral or injectable GLP -1 RAs 
8. Body mass index (BMI) ≤ 40.0 kg/m2. 
5.2 Exclusion criteria  
Subjects are excluded from the trial if any of the following criteria apply:  
1. Known or suspected hypersensitivity to trial product(s) or related products.  
2. Previous participation in this trial. Participation is defined as signed informed consent.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233033] -feeding or intends to become pregnant or is of childbearing 
potential and not using an adequate contraceptive method (adequate contraceptive measures as 
required by [CONTACT_17993]).  
4. Participati on in any clinical trial of an approved or non -approved investigational medicinal 
product within 90 days before screeninga. 
5. Any disorder, except for conditions associated with T2D, which in the investigator’s opi[INVESTIGATOR_111348]’s safety or co mpliance with the protocol.  
6. Any epi[INVESTIGATOR_111349] 90 days prior to the day of screening.  
7. Myocardial infarction, stroke, hospi[INVESTIGATOR_41070] 180 days prior to the day of s creening.  
8. Chronic heart failure classified as being in [LOCATION_001] Heart Association Class IV at screening.  
9. Planned coronary, carotid or peripheral artery revascularisation.  
10. Renal impairment with estimated glomerular filtration rate value of <  30 ml/min/1.73m2 at 
screening16 by [CONTACT_111405].  
11. Impaired liver function, defined as Alanine Aminotransferase ≥ 2.5 times or bilirubin  >1.5 times 
upper normal limit at screening by [CONTACT_111405].  
12. Inadequately treated blood pressure defined as systolic ≥180 mmHg or diastolic ≥110 mmHg at 
screening.  
13. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within 90 days prior to the day of screening . However, short term insulin 
treatment for a maximum of 14 days and prior insulin treat ment for gestational diabetes are 
allowed.  
14. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or 
corticosteroids).  
15. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus 
examination performed within the past 90 days prior to screening or in the period between 
screening and randomisation. Pharmacological pupil -dilation is a require ment unless using a 
digital fundus photography camera specified for non -dilated examination.  
16. Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in -
situ carcinomas of the cervix, or in -situ prostate cancer) within [ADDRESS_1233034] or in the medical records.  
 
5.3 Lifestyle considerations  
5.3.1 Meals and dietary restrictions  
The subjects should be fasting when attending some of the visits, see flowchart (Section 1.2). 
Fasting is defined as at least [ADDRESS_1233035] and other glucose lowering agents should be withheld on the 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233036] one cigarette or equivalent daily.  
5.3.3 Physical activity  
Not applicable for this trial . 
5.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to inclusion/exclu sion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes informed consent date,  
demography, screen failu re details, and eligibility criteria.  For [LOCATION_006]: SAE is also included  as minimal 
information.  
A screen failure session must be made in the interactive web response system (IWRS).  
Individuals who do not meet the criteria for participation in this trial may not  be rescreened. If the 
subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to 
laboratory parameters, re -sampling is not allowed. However, in case of technical issues (e.g. 
haemolysed or lost), re -sampling is allowed for the affected parameters.  
5.5 Run-in criteria, randomisation criteria and dosing day criteria  
Not applicable for this trial.  
6 Treatments  
6.1 Treatments administered  
Investigational medicinal products (IMP s) 
All investigational medical products (IMPs) are listed in Table  6-1. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233037] name:  [CONTACT_111445] 700 units/mL  
(IMP, test product)  Insulin glargine 100 units/mL  
(IMP, reference therapy)  
Dosage form  Solution for injection  Solution for injection  
Route of administration  Subcutaneous  (into the thigh, upper arm 
or abdomen)  Subcutaneous (into the thigh, upper arm or 
abdomen)  
Recommended initial dose  Please refer to Appendix 8   Please refer to Appendix 8   
Dosing instructions  Administer insulin icodec once weekly, 
on the same day each week, at any time of 
the day.  The day of weekly administration 
can be changed if necessary, by [CONTACT_8622] 3 
days. A minimum of 4 days between 
injections should always be ensured.  
Rotation of injection site is 
recommended.  Administer insulin glargine once daily, at 
any time of the day but at the same time 
every day throughout the trial. Rotation of 
injection site is recommended.  
Packaging  3 mL PDS290 pre -filled pen -injector  3 mL S oloSTAR pre-filled pen -injector  
• At randomisation visit (V2) subjects should administer trial drug at site .  
• Subjects should be instructed to discard the needle after each injection and store the 
pen-injector without a needle attached.  
 
Non-investigational medicinal products (NIMP)  
After randomisation subjects should continue their pre -trial non -insulin anti -diabetic background 
medication throughout the entire trial except from sulfonylureas and glinides, which must be 
discontinued at randomisation. The background medication should be maintained at the stable, pre -
trial dose and at the same frequency during the entire treatment period unless due to safety 
concerns.  
In addition, the background medication:  
• is considered to be non -investigational medicinal product (NIMP) . 
• will not be provided by [CONTACT_111406] . 
• should be used i n accordance with standard of care or local label in the individual country at 
the discretion of the investigator.  
Auxiliary supplies  
Auxiliary supplies comprise supplies other than trial products. Auxiliary supplies will be provided 
in accordance with the  trial materials manual, please see Table  6-2. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233038].  
Blood glucose  (BG)  
meter   At randomisation (V2) subjects must be instructed in how to use the BG meter and the 
BG meter should be linked to the eDiary as described in the eDiary site guide.  
Please refer to the [COMPANY_002] manufacturer’s  guide.  
Continuous glucose 
monitoring  (CGM)  
system  At randomisation (V2) subjects must be instructed in handling of the CGM.  
Please refer to the Dexcom G6® manufacturer’s guide provided.  
eDiary  Subject Mobile App, HCP Web Portal, & Cloud Service . 
Please refer to the eDiary site guide.  
• Information about the PDS290 pre -filled pen -injector can be found in the directions for use 
provided in the eDiary.  
• Information about the SoloSTAR pre-filled pen-injector can be found in the summary of 
product characteristics . 
• Training in the pen -injectors  is the responsibility of the investigator or a delegate and must be 
repeated during the trial at regular intervals, as specified in the flowchart (see Section 1.2) in 
order to ensure correct use of the pen -injector.  
6.1.1 Medical devices  
[IP_ADDRESS]  Investigational medical device  
Not applicable for this trial . 
[IP_ADDRESS]  Non-investigational medical devices  
Non-investigational medical devices are listed as auxiliary supplie s (Table  6-2). 
For the countries where BG meter  and CGM are not approved, please refer to the Appendix 9  
(Section 10.9) country -specific requirements for further information . 
6.2 Preparation/handling/storage/accountability  
Only subjects randomised to treatm ent may use trial product and only delegated site staff may 
supply trial product.  
• Acceptable temperature ranges and conditions for storage and handling of each trial product 
when not in use and when in use are described in the trial material manual and tri al product 
label.  
• Each site will be supplied with sufficient trial product for the trial on an ongoing basis. Trial 
product will be distributed to the sites according to screening and randomisation . 
• The investigator or designee must confirm that appropriat e temperature conditions have been 
maintained during transit for all trial products received, and that any discrepancies are reported 
and resolved before use of the trial products.  
• All trial products must be stored in a secure, controlled, and monitored (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the investigator 
and delegated site staff.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  31 of 94 
 
• The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified con ditions. The trial product must not be dispensed to any subject before it 
has been evaluated and approved for further use by [CONTACT_3454]. Additional details 
regarding handling of temperature deviations can be found in the trial material manual . 
• The invest igator or designee is responsible for drug accountability and record maintenance (i.e. 
receipt, accountability and final disposition records).  
• The investigator or designee must instruct the subject in what to return at next visit . 
• Each single pen -injector  should be accounted.  
• Destruction of trial products can be performed on an ongoing basis and will be done according 
to local procedures after accountability is finalised by [CONTACT_41138].  
• All returned, un -used,  expi[INVESTIGATOR_881841] (for technical complaint samples, see 
Section 10.5) must be stored separately from non -allocated trial products. No temperature 
monitoring is required.  
• Non-allocated trial products including expi[INVESTIGATOR_41073], at the latest at closure of the site.  
6.3 Measures to minimise bias: Randomisation and blinding  
• This is an open  label trial; however, the sp ecific treatment for a subject will be assigned using 
an IWRS. The site will access the IWRS before the start of trial product administration for 
each subject. Potential bias will be reduced by [CONTACT_111407] . 
• All subjects will be c entrally screened and randomised using an IWRS and assigned to the next 
available treatment according to randomisation schedule. Trial product will be 
dispensed/allocated at the trial visits summarised in the flowchart (see Section 1.2). 
 
6.[ADDRESS_1233039] administration 
will be assessed by [CONTACT_111408]:  
• Drug accountability informatio n.  
• Review of eDiaries including SMPG profiles, insulin dose and hypoglycaemia reporting . 
• Evaluating glycaemic control and adherence to the visit schedule . 
• If any suspi[INVESTIGATOR_17946] -compliance arises the site must enter into a dialogue with the subject , 
re-emphasizing the importance of compliance and uncover barriers to compliance. This 
dialogue must be documented in the medical record.  
6.[ADDRESS_1233040] rece ives 
from screening (V1) until  end of trial  visit (V63) must be recorded along with:  
• Generic name [CONTACT_881875]:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  32 of 94 
 
• Indication   
• Dates of administration including start and stop date . 
Concomitant medication (diabetes)  
Any anti -diabetic medication other than the trial product that the subject receives from screening 
(V1) until  end of trial visit ( V63) must be recorded in a separate concomitant medication (diabetes) 
form in the electronic case report form  eCRF.  
The following information must be recorded for or al anti -diabetic drug, GLP -[ADDRESS_1233041] -treatment insulin in the follow -up period : 
• Generic name [CONTACT_111446] (for insulin products: only trade name) . 
• Dates of administration including start and stop date.  
• Doses and frequency (e.g. once daily, twice daily).  
Until end of treatment (V 61) only randomised treatment (trial products and pre -trial non -insulin 
anti-diabetic background medication  except for sulfonylureas and glinides which must be 
discontinued at randomisation) is allow ed, unless due to safety reasons at the discretion of the 
investigator. If the investigator chooses to initiate anti -diabetic medication or change dose of pre -
trial anti -diabetic background medication prior to end of treatment (V 61), this should be registe red 
in the eCRF as change in concomitant medication (diabetes).  
Changes in concomitant medication including anti -diabetic medication  and other indications must 
be recorded at each visit. If a change is due to an adverse event , then this must be reported 
according to Section 8.3. 
For information regarding concomitant medication collection including anti -diabetic medication  
and other indications for subjects who discontinue trial product see Section 7. 
6.5.1 Rescue medication or Rescue therapy  
Not applicable for this trial . 
6.6 Dose modification  
Doses are adjusted according to blood/plasma glucose values as described in 
Appendix  8 (Section  10.8). 
6.6.[ADDRESS_1233042] -trial treatment includes a new insulin 
treatment, please refer to the titration guideline in Appendix 8  (Section 10.8).  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233043] 
discontinuation/withdrawal  
Treatment of a subject may be discontinued at any time during the trial at the discretion of the 
investigator  for safety, behavioural, compliance or administrative reasons.  
Efforts must be made to have the subjects who discontinue trial product attend the end of treatment 
visit (V61) as soon as possible to collect the required data for the analysis of the primary end point. 
Two follow -up visits, V62 and V63, must be performed after discontinuation of the trial product. 
Visits V62 and V63 must be conducted [ADDRESS_1233044] should keep and use the eDiary, and return it at 
follow -up 2 visit (V63).  
If a subject discontinues  the treatment prior to week 48  (V42) , the subject should be asked to wear 
CGM from week 48 (V42) to week 52 (V46) in accordance with the flowchart (see Section 1.2).  
The investigator should change subject  status in the HCP web portal to 'Follow -up' at the end of 
treatment visit to ensure that the subject should no longer report insulin dose.   
Continue to collect, record and report AEs as described in Section 8.3. AEs and anti-diabetic 
medication should be collected and recorded in the eCRF  until the discontinuation follow -up visit 
(V61A ) for discontinued subjects, no other concomitant medication will be collected. Please, refer 
to Section  6.[ADDRESS_1233045] with discontinued subjects by [CONTACT_17084]/or site 
visits to motivate subjects to attend the  visits until the discontinuation follow -up visit (V 61A). Site 
contact [CONTACT_111409].  
7.[ADDRESS_1233046]:  
1. Safety concern related to trial product or unacceptable intolerability  
2. Pregnancy  
3. Intention of becoming pregnant  
4. Simultaneous use of an approved or non -approved investigational medicinal product in another 
clinical triala 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  34 of 94 
 
5. Lack of efficacy, defined as fulfilment of ALL  4 criteria below:  
a. No reduction in HbA 1c measured by [CONTACT_41140] (V2) to 
V12, to V20, to V28, to V 36, to V40, to V46, to V51, or to V55 AND  
b. the pre -breakfast SMPG readings on 3 consecutive days higher than 240 mg/dL 
(13.3 mmol/L) within the last two weeks period despi[INVESTIGATOR_111352]  
c. a confirmatory fasting plasma glucose exceeding 240 mg/dL (13.3 mmol/L) 
measured by [CONTACT_12115]. The subject should come in for an unscheduled visit 
as soon as possible (within one week) , the next scheduled visit should not be awaited 
AND  
d. no treatab le intercurrent cause (e.g. non -compliance) for the hyperglycaemia at the 
investigator’s judgment .  
a Simultaneous participation in a trial with the primary objective of evaluating an approved or non -approved 
investigational medicinal product for preventio n or treatment of COVID -[ADDRESS_1233047], who does not fulfil the eligibility (inclusion/exclusion) criteria, must not be randomised. 
Randomisation in violation of any of the elig ibility criteria is good clinical practice (GCP) non -
compliance and must be reported to the sponsor without delay. This will be handled as an important 
protocol deviation, and the independent ethics committee/institutional review board (IEC/IRB) and 
regula tory authorities must be notified according to local requirements.  
Subjects that are randomised in violation of inclusion and exclusion criteria can be allowed to 
continue in the trial and receive trial product if there are no safety concerns as evaluated  by [CONTACT_111410]  (not applicable for [LOCATION_006]) . 
7.1.[ADDRESS_1233048] discontinuation/withdrawal from the trial  
A subject may withdraw consent at any time at his/her own request. If a subject withdraws consent, 
the investigator must ask the subject if he/she is willing, as soon as possible, to have assessment 
performed according to  the end of treatment visit (V61). See the flowchart (Section  1.2) for data to 
be collected.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233049] withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must do cument this in the medical record.  
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are ob tained, the primary reason for withdrawal must be specified in the end of trial 
form  in the eCRF.  
7.2.[ADDRESS_1233050] will be considered los t to follow -up if he /she repeatedly fails to return for scheduled visits 
and is unable to be contact[CONTACT_55654].  
The following actions must be taken if a subject fails to return to the site for a required visit:  
• The site must attempt to contact [CONTACT_881862]/or should continue in the trial.  
• Before a subject is deemed lost to follow -up, the investigator or designee must make every 
effort to regain contact [CONTACT_1155] (where possible, at least three telephone calls and, if 
necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact [CONTACT_9300]'s source document.  
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of `lost to follow -up'. 
8 Trial assessments and procedures  
The following sections describe the assessments and procedures, while their timing is summarised 
in the flowchart  (see Section 1.2). 
• Informed consent must be obtained before any trial related activity, see 
Appendix  1 (Section  10.1.3 ). 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all inclusion criteria and none of the exclusion criteria.  
• The investigator will maintain a sc reening log to record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable.  
• At screening, subjects will be provided with a card stating that they are participating in a trial 
and giving contact [CONTACT_111411].   
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct.   
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  36 of 94 
 
• Assessments should be carried out according to the  clinic’s standard of practice unless specified 
in the current section. Efforts should be made to limit the bias between the assessments. The 
suggested order of the assessments at randomisation visit (V2) is as follows:  
• Blood sample collection  
• Other asses sments to confirm eligibility  
• Randomisation in IWRS  
• Continuous glucose monitoring  fitting and training  
• The Investigator should create a subject profile and record administrative 
information (e.g. subject ID, year of birth and gender and treatment arm) in the 
HCP web portal  
• Subjects should be provided with an eDiary and instructed in how to use it  
• The BG meter should be connected with the eDiary  
• A fasting SMPG should be measured using the BG meter  
• Dosing of trial product . 
• For information regarding the eDiary and HCP web portal please refer to the site guide.  
• Please refer to Section 6.4 for drug treatment compliance.  
• All data entered in the eDiary is considered source data. The investigator should review all the 
data for the subjects through the HCP web portal, before or during each visit/phone contact.  
• Review of eDiary, ECG, laboratory reports, eye - and physical examin ations must be 
documented either on the documents or in the subject's source documents. If clarification of 
entries or discrepancies in the eDiary is needed, the subject must be questioned, and a 
conclusion made in the subject's source documents, the eDiar y should be updated 
retrospectively if applicable. Care must be taken not to bias the subject.  
• Source data of clinical assessments performed and recorded in the eCRF must be available and 
will usually be in the subject’s medical records. Additional recordi ng to be considered source 
data includes, but is not limited to;  laboratory reports, BG meter , CGM, pi[INVESTIGATOR_499] , and ECG 
recordings.  
• Repeat samples may be taken for technical issues and unscheduled samples or assessments may 
be taken for safety reasons. Please refer to Appendix 2  (Section 10.2) for further details on 
laboratory samples . 
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart ( see Section 1.2). 
8.1.1 Self-measured plasma glucose (SMPG)  
Subjects will be provided with a blood glucose (BG) meter including auxiliaries. The BG meters 
use test strips calibrated to plasma values. Therefore, all measurements performed with capi[INVESTIGATOR_881842], which will be shown on the 
display .  
The B G meter provided by [CONTACT_111413], as described in the flowchart ( see Section 1.2). 
A baseline SMPG value, in fasting condition, should be collected using the BG meter at V2.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233051] SMPG daily from week 0 (V2) to end 
of trial (V63) and to transfer t he measured SMPG values into the eDiary.  
Selected titration data (e.g. certain SMPGs and dose data) from the eDiary will be used during the 
trial for central titration surveillance, to ensure compliance with the titration guideline in 
Appendix  8 (Section 10.8) and will not be reported in the clinical trial report. All data will be stored 
by N ovo Nordisk (see Appendix 1 , Section 10.1). 
8.1.2 Continuous glucose monitoring  (CGM)  
Subjects will be equipped with a CGM device during the treatment periods from week 0  (V2) to 
week 4  (V6) and from week 22  (V24) to week  26 (V28) and from week  48 (V42) to week 52  (V46), 
and from week 74  (V57) to week 78  (V61) and during the follow -up period from week 78  (V61) to 
week 83  (V63).  
The CGM system used in this trial will be the Dexcom G6®. 
The CGM readings will be blinded to both the subject and investigator and will not be used for any 
insulin dose titration or hypoglycaemic epi[INVESTIGATOR_41076].  
If a subject withdraws con sent during the trial, a site visit should be scheduled in order to remove 
the CGM sensor and upload the data from the receiver.  
CGM fitting and training  
The site staff will closely supervise and assist on fitting of the sensor and transmitter on the subje ct 
during the site visits. Training in the CGM is the responsibility of the investigator or site staff at the 
relevant visits. For information on fitting, and changing of the CGM parts, please refer to the 
manufacturer’s manual and subject guide provided.  
CGM sensor check  
The site staff should ensure that the subject has fitted the sensor correctly and that the CGM 
receiver is working. This will be done in person during the site visit, as specified in the flowchart 
(see Section  1.2). At the end of treatment visit (V 61), the site should ensure the subject can change 
the sensor at home weekly during the follow -up period.  
CGM upload  
Data stored on the CGM  receiver must be uploaded at the site by [CONTACT_111414]. The upload will be documented by [CONTACT_111415].  
The serial number of the CGM receiver must be recorded in the eCRF at the st art of each CGM 
period. In case the CGM receiver is being replaced, the serial number should be updated.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  38 of 94 
 
8.1.3 Clinical efficacy laboratory assessments  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the flowchart (see Section 1.2) and the laboratory manual . 
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the flowchart  (see Section 1.2). 
A concomitant illness  is any illness that is already present at the time point from which AEs are 
collected or found as a result of a screening procedure or other trial procedures performed before 
exposure to trial product.   
Medical history is a medical event that the subject experienced  prior to the time point from which 
AEs are collected.  Only relevant medical history as judged by [CONTACT_364065].  
In case of an abnormal and clinically significant finding fulfilling the definition of a concomitant 
illness or medical history, the investigator must record the finding on the medical 
history /concomitant illness form . 
8.2.1 Insulin dose  
The prescribed  insulin doses will be determined  by [CONTACT_111417]  (see Appendix 8 , Section 10.8). 
During the trial, starting at randomisation (V2), subjects must be instructed to report date , dose and 
time of once weekly insulin or once daily insulin in the eDiary. In the follow -up perio d if the 
subject switches to a new basal insulin, the subject should also report date, dose and time of the new 
basal insulin in the eDiary.  
Please refer to Appendix 8  (Section 10.8) for more information.  
The investigator must record the following in the eCRF : 
• First and last date on trial product  
• First and last dose of trial  product . 
For dosing of anti -diabetic medication prescribed in the follow -up period please see section 6.5 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  39 of 94 
 
8.2.2 Physical examinations  
A physical examination will include assessments of:  
• Head, ears, eyes, nose, throat, neck  
• Cardiovascular system  
• Respi[INVESTIGATOR_2133]  
• Gastrointestinal system  
• Central and P eripheral Nervous System  
• Musculoskeletal system  
• Skin.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
The physical examination will be recorded in the eCRF as either ‘normal’ or ‘abnormal’. If 
‘abnormal’ , a comment must be given together with an assessment of clinical significance (yes/no).  
Abnormal, clinically significant findings at screening should be recorded as concomitant illness in 
the eCRF. At the following visits, any new abnormal, clinically si gnificant findings or clinically 
significant deteriorations from baseline should be reported as an adverse event  
(Appendix  3, Section  10.4). 
Body measurements (height and weight) will also be measured and recorded . Height will be 
measured and recorded at screening visit (V1). Weight will be measured and recorded throughout 
the tr ial as specified in the flowchart (Section 1.2). 
• Body weight should be measured in kilogram (kg) or pounds (lb) without coat and shoes 
wearing only light clothing. Body weight will be recorded to one decimal.  
• Body weight should be assessed with the same equipment throughout the trial, if possible.  
• Height should be measured in centimetres (cm) or inches (in) without shoes. Height will be 
recorded to the nearest whole number.  
• From the body weight and height, the BMI will be calculated  in the eCRF.  
8.2.3 Vital signs  
• Pulse rate, as well as systolic and diastolic blood pressure will be assessed . 
• Blood pressure and pulse rate measurements  should be preceded by [CONTACT_2669] [ADDRESS_1233052] in a quiet setting without distractions (e .g. no use of television, mobile  phones).  
• Blood pressure and pulse rate measurements will be assessed sitting with a completely 
automated device. Manual techniques must be used only if an automated device is not 
available.  
• Blood pressure and pulse rate at screening (V1), V16, V28, V46, and end of treatment (V61) 
will consist of [ADDRESS_1233053] 
two readings on systolic or diastolic blood pressure differ by >[ADDRESS_1233054] be recorded in the eCRF.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  40 of 94 
 
• Pulse rate will be measured in connection to the blood pressure measurements. Record the pulse 
rate for the last [ADDRESS_1233055]  2 measurements.  
8.2.4 Electrocardiograms  
• A [ADDRESS_1233056] be performed by [CONTACT_111418] (Section 1.2). 
• The ECG should be preceded by [CONTACT_2669] [ADDRESS_1233057] in a supi[INVESTIGATOR_050]/sitting 
position in a quiet setting without distractions (e.g. no use of television, mobile  phones).  
• The ECG must be interpreted, signed and dated by [CONTACT_881863] . 
• The ECG required at screening can be obtained within [ADDRESS_1233058].  
• The ECG required at visit V46 and at the end of treatment visit (V61) can be obtained within [ADDRESS_1233059] be available for evaluation at visit V46 and at the 
end of treatment visit (V61), respectively.  
• Abnorma l, clinically significant findings at screening should be recorded as concomitant illness 
in the eCRF. At the following visits, any new abnormal, clinically significant findings or 
clinically significant deteriorations from baseline should be reported as a n adverse event  
(Appendix  3, Section 10.4).  
8.2.[ADDRESS_1233060] or another suitably qualified health 
care provider (e.g. optometrist) must be available and evaluated by [CONTACT_111419]. The eye examination should be performed as a fundus 
photography (e.g. 2 -field 60 degree or better, colour or red -free) or by [CONTACT_41157] -lamp biomicroscopy 
examination (e.g. using a pre -corneal or corneal contact [CONTACT_41158]). Pharmacological pupil -
dilation is a requirement unless using a digital fundus photog raphy camera specified for non -dilated 
examination.  
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. Eye examinations performed prior to randomisation visit (V2) are acceptable 
if results are available for evaluation before randomisation. If the ap plicable eye examination was 
performed before the subject signed the informed consent form, it must be documented that the 
reason for performing the examination was not related to this trial.  
Eye examinations required at the end of treatment (V61) visit ca n be performed within 2 weeks 
prior to the visit, if results are available for evaluation at the visit. For discontinued subjects, eye 
examination can be performed up to 2 weeks after the end of treatment visit. The investigator 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233061] be recorded as concomitant illness/medical history. While relevant findings occurring after 
randomisation should be reported as an adverse event , please refer to Section  8.3 and Appendix  3 
(Section 10.4).  
8.2.6 Clinical safety laboratory assessments  
All protocol -required laboratory assessments, as defined in Appendix 2  (Section 10.2), must be 
conducted in accordance with the flowchart (see Section 1.2) and laboratory manual . 
8.3 Adverse events (AEs)  and serious adverse events  (SAE)  
The investigator is responsible for detecting, documenting, recording and following up on events 
that meet the def inition of an AE or SAE.  
The definition of AEs and SAEs can be found in Appendix 3  (Section 10.3), along with a 
description of events for adjudication and  AEs requiring additional data collection.  
Some AEs require additional data collection on a specific event form. This always includes 
medication, misuse and abuse of IMP. The relevant events are listed  in Table  8-1, together with 
events for adjudication.  
Hypoglycaemic epi[INVESTIGATOR_364041] a hypoglycaemic epi[INVESTIGATOR_364042]. 
Non-serious hypoglycaemic epi[INVESTIGATOR_364043]. If the 
hypoglycaemic epi[INVESTIGATOR_197620], then, in addition to the hypoglycaemic 
epi[INVESTIGATOR_364044], an AE form and a safety information form must be filled in in the eCRF, please refer 
to Appendix 3 . For more information on hypoglycaemic epi[INVESTIGATOR_1841], please refer to Appendix 7  
(Section 10.7). 
Table  8-1 AEs requiring additional data collection (serious and non -serious AEs), and 
events for adjudication   
Event type   AE requiring additional 
data collection  Event for adjudication  
 
Medication error  X  
Misuse and abuse  X  
Acute coronary syndrome (acute myocardial 
infarction or unstable angina pectoris requiring 
hospi[INVESTIGATOR_11956])   X 
Cerebrovascular eventsa (stroke or transient 
ischemic attack)   X 
Heart failure (requiring hospi[INVESTIGATOR_111355])   X 
Death   X 
Hypersensitivity  X  
Injection Site Reaction  X  
a All cerebrovascular events are to be reported and sent for adju dication, however the EAC will only confirm strokes.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  42 of 94 
 
A detailed description of the events mentioned in the above table can be found in 
Appendix  3 (Section  10.3.3 ). 
Events for Adjudication  
Event adjudication will be performed in randomised subjects and will be evaluated by [CONTACT_364066] a blinded manner, please refer to Section [IP_ADDRESS] .  
There are four ways to identify events relevant for adjudication as described below:  
• Investigator -reported events for adjudication: investigator selects the appropriate AE 
category relevant  for adjudication ( Appendix 3 , Section 10.3.3 ).   
• AEs reported with fatal outcome .  
• AE search (standardised screening): All AEs not reported with an AE category relevant for 
adjudication will undergo screening to identify potential events for adjudication. 
Investigators will be notified of these events in the eCRF.  
• EAC -identified events:  Unreported events relevant for adjudication identified by [CONTACT_111421].  
Investigators will be notified of these events in the eCRF and has the option to report the 
EAC -identified ev ent. 
For each event relevant for adjudication an event type specific adjudication form should be 
completed in the eCRF within 14 days.  
Copi[INVESTIGATOR_111356] (EAS) as soon as 
possible and preferably w ithin [ADDRESS_1233062] be collected from the randomisation visit (V2)  and until the end of trial 
visit as specified in the flowchart  (see Section 1.2). For subjects  discontinuing trial product 
prematurely AEs must be collected until the discontinuation follow -up 2 visit (V61A ). For AE 
reporting in [LOCATION_006], please  refer to  the [LOCATION_006] specific  requirements in Appendix 9  (Section 10.9). 
Medical occurrences that take place or have onset prior to the time point from which AEs are 
collected will be recorded as concomitant illness/medical history. AE and SAE reporting timelines 
can be found in Appendix 3 (Section 10.3). All SAEs must be recorded and reported to Novo 
Nordisk within [ADDRESS_1233063] submit any updated SAE data to Nov o Nordisk 
within 24 hours of it being available.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233064] has been 
discontinued f rom/completed the trial, and the investigator considers the event to be 
possibly/probably related to the trial product or related to trial participation, the investigator must 
promptly notify Novo Nordisk.  
8.3.2 Method of detecting AEs and SAEs  
The method of rec ording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 3  (Section 10.3). 
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the subject is the preferred  method to inquire about events.  
8.3.3 Follo w-up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs  should be followed until final outcome of the event or the 
subject is lost to follow -up as describ ed in Section 7.3. Further information on follow -up and final 
outcome of events is given in Appendix 3  (Section 10.3). 
8.3.[ADDRESS_1233065] under clinical  investigation. Novo Nordisk 
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and investigators. This also includes suspected unexpected serious 
adverse reactions (S[LOCATION_003]R).  
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs) from Novo Nordisk will review and then file it along 
with the investigator's brochure and will notify the IRB/IE C, if appropriate according to local 
requirements.  
8.3.[ADDRESS_1233066] becomes pregnant, the investigator should inform Novo Nordisk within 14 
calendar days of learning of the pregnancy and should follow the procedures outlined in 
Appendix  4 (Section 10.4). 
8.3.6 Cardiovascular and death events  
Cardiovascular and death events will be handled and reported according to Section 8.3. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  44 of 94 
 
8.3.7 Disease -related events and/or disease -related outcomes not qualifying as an AE or 
SAE  
Not applicable for this trial.  
8.3.[ADDRESS_1233067] expedited 
reporting by [CONTACT_473]. Only adverse events fulfilling the seriousness criteria are considered for expedited 
reporting in this trial . 
8.3.9 Technical complaints  
Technical complaints will be collected for all products listed on the technical complaint form.  
Instructions for reporting technical complaints can be found in Appendix 5  (Section 10.5). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technical complaint form.  
8.[ADDRESS_1233068] be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3  (Section 10.3) for further details.  
In the event of an overdose, the investigator should closely monitor the subject for overdose -related 
AE/SAE and laboratory abnormalities until the blood glucose is normalised and (or) 
signs/symptoms have been relieved.  
A specific overdose for insulin icodec cannot be define d; however, hypoglycaemia may develop 
over sequential stages if the doses administered are too high relative to the subject’s requirements.  
• Mild hypoglycaemia can be treated by [CONTACT_41147].  
• Severe hypoglycaemia, wher e the subject is not able to treat him/herself, can be treated by 
[CONTACT_41148] (0.5 to 1 mg) given intramuscularly or subcutaneous ly by a trained person, or by 
[CONTACT_881864] a medical professional. Glucose must also be given 
intravenously , if the subject  dose not respond to glucagon within [ADDRESS_1233069] . 
For more information on overdose, also consult the current version of the insulin icodec 
investigator’s brochure11 or insulin glargine  EMA summary of product characteristics14, US 
prescribing information13, or any locally approved label.  
8.5 Pharmacokinetics  
Not applicable for this trial . 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233070] signs and symptoms of systemic 
hypersensitivity.  
For subjects randomis ed to insulin icodec : In the event of a systemic hypersensitivity (not locally at 
the injection site), the subject  should be called in as soon as possible to have additional blood 
samples taken in order to analyse the following parameters:  
• Tryptase (optima l 0.5-[ADDRESS_1233071] the hypersensitivity reaction)  
• Total immunoglobulin E (IgE) antibodies  
• Anti-insulin icodec IgE antibodies  
• Anti-insulin icodec binding antibodies  
• Anti-human insulin IgE antibodies . 
The blood sampling should be repeated [ADDRESS_1233072] 
administration of trial drug.  
For details related to blood sampling, plasma preparation and storage, please refer to the labor atory 
manual.  
Analysis will be performed by [CONTACT_49705] a Novo Nordisk appointed special laboratory 
(please refer to Attachment I). The results will be reported in a separate report and attached to the 
clinical trial report . 
If the reaction is classifi ed as a SAE, the results from the hypersensitivity tests will also be reported 
to Novo Nordisk Safety Operations for inclusion in the ARGUS database and included in the 
narratives of the clinical trial report . 
For retention of residual hypersensitivity sam ples, please refer to Section 10.6. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233073] take digital pi[INVESTIGATOR_881843], using any device available (mobile phone, camera etc.) and thereafter as often as 
judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_41084], 
date and time, time after dosing and a ruler for scaling. All  pi[INVESTIGATOR_111358].  
8.10 Health economics  
Not applicable for this trial.  
9 Statistical considerations   
9.1 Statistical hypotheses  
The primary hypothesis to be tested is that insulin icodec is non -inferior to insulin  glargine in terms 
of change from baseline to week  52 in HbA 1c. 
Formally, let D be the treatment difference ‘insulin icodec’ minus ‘insulin glargine ’ of the change in 
HbA 1c from baseline to week 52. The null -hypothesis will be tested against the alternativ e 
hypothesis of non -inferiority as given by  
H0: D≥0.30% against HA: D <0.30%  
The non -inferiority margin of 0.3% -point is chosen based on the recommendation in the FDA 
guidance for industry on developi[INVESTIGATOR_111359].17 Also, this margin is 
considered to provide sufficient assay sensitivity based on the below considerations:  
• The margin does not represent an unacceptable loss of efficacy with insulin icodec relative 
to treatment with a basal insulin analogue . 
• It represents less than 50% of a suitable conservative estimate of insulin glargine’s 
treatment effect on HbA 1c in a placebo -controlled trial in insulin naïve subjects ( -0.85% -
point [ -1.04; -0.66] 95% CI versus placebo), which demonstrated insulin glargine’s 
superiority.18 
The following sections detail the secondary confirmatory hypotheses. In order to control the overall 
Type I error at a 5% level, two -sided, a hierarchical testing procedure will be used. If non -
inferiori ty in glycaemic control is concluded in the primary analysis, confirmatory testing proceeds 
down the following hierarchy as long as the confirmatory secondary hypothesis at a given stage is 
confirmed:  
• Insulin icodec is superior to insulin glargine in term s of ‘time in target range 3.9 – 10.0 
mmol/L (70 -180 mg/dL)’ from week 48 to week 52 . 
• Insulin icodec is superior to insulin glargine in terms of change from baseline to week 52 in 
HbA 1c. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233074] to percent ‘time in target range 3.9 – 10.0 
mmol/L (70 -180 mg/dL)’ from week 48 to week 52 for ‘insulin icodec’ minus ‘insulin glargine’. 
The null -hypothesis will be tested against the alternative hypothesis of superior ity as given by : 
H0: DT≤0% against HA: DT >0%  
As above, let D be the mean treatment difference ‘insulin icodec’ minus ‘insulin glargine’ of the 
change in HbA 1c from baseline to week 52. The null -hypothesis of insulin icodec not superior will 
be tested agai nst the alternative hypothesis of superiority as given by : 
H0: D≥0% against HA: D<0%  
9.[ADDRESS_1233075] 300 subjects 
completing 78 weeks treatment with insulin icodec  as well as having sufficient marginal power for 
the confirmatory secondary hypotheses . In the recent open  label study NN1250 -4252 with 88 weeks 
of treatment with insulin degludec 200 units/mL and insulin glargine 300 units/mL, around 12% in 
total had discontin ued treatment after 78 weeks. Assuming 85% will complete treatment in the 
present trial, 300/0.85 = 353 subjects starting treatment with insulin icodec is needed to obtain 300 
subjects completing treatment. With equal randomisation, a minimum of 706 random ised subjects 
in total is required.  
The sample size calculation also considers the power for declaring non -inferiority with a non-
inferiority  margin of 0.3% -point with respect to the primary endpoint, change in HbA 1c from 
baseline to week 52, for the spec ified estimand and the full analysis set (primary analysis set). 
Based on NN1250 -4252, 10% is expected to experience an intercurrent event, as specified above, 
during the first 52 weeks of treatment.  
It is assumed that there is no difference in HbA 1c betwe en the treatment arms for subjects 
completing randomised treatment without treatment with bolus insulin for more than 2 weeks and a 
treatment difference of 0.3% -point in favour of the comparator for subjects either discontinuing 
treatment prematurely, has treatment with bolus insulin for more than 2 weeks, or withdraws from 
trial. Thus, with 10% expected to experience any of the specified intercurrent events before week 
52, this leads to an assumption of a mean treatment difference of 0.10*0.3=0.03% -point f or the 
specified estimand in the overall population.  
In NN1250 -4252, a standard deviation (SD) of 0.96% -points was observed in the glargine arm at 48 
weeks. In NN1250 -3579, an open  label study of insulin degludec 100 units/mL vs insulin glargine 
100 units/ mL in insulin naïve subjects, a SD of 0.92% -points was observed in the glargine arm at 52 
weeks. Based on this, the SD is assumed to be 1.0% -point. In order to ensure a marginal power of 
80% to detect if the true treatment difference in HbA 1c is 0.2% -point , 0.18% -point when adjusted 
for the 10% expected to experience any of the specified intercurrent events, 970 subjects are 
needed.  With 970 subjects and the assumption  of a mean treatment difference of 0.03% , there is 
sufficient power of 9 9% for declaring non-inferiority  with a non-inferiority  margin of 0.3% -point 
with respect to the primary endpoint.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  48 of 94 
 
From the above assumptions and requirements, a total of 970 subjects will be randomised 1:1. 
Assuming 25% screening failures, approximately [ADDRESS_1233076] and 485 subjects randomly assigned to the control 
group. This sample size appears to be reasonable also under deviations from the assumed treatment 
difference as illustrated in Table   9-1 displaying power for various alternative treatment differences 
and SDs. 
The confirmatory secondary endpoint is ‘time in target range 3.9 – 10.0 mmol/L (70 -180 mg/dL)’ 
from week 48  to week 52 . In a previous trial, NN1250 -3874, the SD of the percent of time -in-range 
was 13.9. It is assumed that the SD is 15% and that 0.90* 970=[ADDRESS_1233077] time -in-range 
measurements at 52 weeks. With the as sumptions above and a true difference of 4% in time -in-
target range, there is 98% power to confirm the confirmatory secondary hypothesis.  
Table  9-[ADDRESS_1233078] deviations . 
SD  % intercurrent events/ 
Treatment difference   
8% / 0.184  10% / 0.18  12% / 0.176  
0.9 88.9%  87.5%  86.0%  
1.0 81.7%  80.0%  78.2%  
1.1 74.0%  72.1%  70.2%  
SD: standard deviation. Power is computed for 1:1 randomisation and 970 subjects randomised.  
9.3 Populations for analyses  
The following population s are defined : 
Population  Description  
Randomised  All subjects randomised . 
Full analysis set  Full analysis set: All subjects randomised. Subjects will be analysed according to 
the randomised treatment.  
Safety  analysis set  All subjects randomly assigned to trial treatment and who take at least one dose of 
trial product. Subjects are analysed acco rding to the treatment they actually 
received.  
In exceptional cases, subjects or observations may be elimin ated from the full analysis set. In such 
case the reasons for their exclusion will be documented before unblinding. The subjects and 
observations e xcluded from analysis sets, and the reason for this, will be described in the clinical 
trial report . 
The following periods will be considered for the data collected:  
In-trial period  
The in -trial period starts at randomisation and ends at the date of:  
• The last direct subject -site contact  
• Withdrawal for subjects who withdraw their informed consent  
• The last subject -investigator contact [CONTACT_36330] -up (i.e. possibly an unscheduled phone visit)  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  49 of 94 
 
• Death for su bjects who die before any of the above . 
For subjects not randomised but exposed to trial product the in -trial period starts at the date of first 
dose of trial product  (not applicable for [LOCATION_006]) . The end date is as defined as above.  
On-treatment period  
The on -treatment period starts at the date of first dose of trial product as recorded on the eCRF, and 
ends at the first date of any of the following:  
• The end of trial  visit ( V63) 
• The last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly 
insulin  (corresponding to 5 weeks after the end of the dosing interval for both treatment arms)  
• The end -date for the in -trial observation period . 
The on -treatment period represents the time period in which a subject is considered exposed to tri al 
product.  
Main -on-treatment period  
The main -on-treatment period starts at the date of first dose of trial product as recorded on the 
eCRF, and ends at the first date of any of the following:  
• The end date of the on -treatment period  
• Week 52 (V46) . 
All efficacy endpoints will be summarised and analysed using the full analysis set and the ‘in -trial’ 
period. Safety endpoints will be evaluated using both the main -on-treatment and the on -treatment 
period with descriptive statistics being based on the saf ety analysis set and statistical analyses being 
based on the full analysis set  unless otherwise specified.  
9.4 Statistical analyses  
The statistical analysis plan (SAP) will be finalised prior to first subject first visit, and it will 
include a more technical a nd detailed description of the statistical analyses described in this section.  
This section is a summary of the planned statistical analyses of the most important endpoints 
including primary and secondary endpoints.  
9.4.1 General considerations  
Presentation of r esults from a statistical analysis will include the estimated mean treatment 
difference (or ratio) presented together with the two -sided 95% confidence interval and the 
corresponding two -sided p -value.  
In the statistical models, explanatory factors will be  coded as follows:  
• Treatment: Once weekly insulin icodec, insulin glargine  
• Region: Asia, Europe, North America, South America  
• The regions will be defined as follows:  
• Asia: India, Japan  
• Europe: Croatia, Italy, Israel, Poland, Russia, Slovakia, Spain, Unite d Kingdom  
• North America: [LOCATION_002]  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  50 of 94 
 
• South America: Mexico  
The last available assessment made prior to the first dose will be used as the baseline value.  
All endpoints based on CGM measurements will be derived the following way. The percentage of 
time spent in a given glycaemic range will be calculated as [ADDRESS_1233079] 70% of the planned CGM 
measurements during the last four weeks of treatment are available for endpoint data to be included 
in the analysis.19 
9.4.2 Primary endpoint  
The primary endpoint is change in HbA 1c from baseline  to week 52.  
The ‘treatment policy’ estimand, will be estimated based on  the full analysis set using all HbA 1c 
measurements obtained at the week 52 visit, especially including measurements from subjects 
discontinuing their randomised treatment or initiating treatment with bolus insulin for more than 2 
weeks. Missing HbA 1c values at the week 52 visit  (regardless of treatment completion status) will 
be imputed from trial participants, who have discontinued their randomised treatment or initiated 
bolus insulin treatment for more than [ADDRESS_1233080]:  
1. First, one thousand (1000) copi[INVESTIGATOR_364046] 1c.  
2. Second, for subjects who discontinued their randomised treatment or initiated treatment with 
bolus insulin for more than [ADDRESS_1233081] available planned on -
treatment without initiation of more than 2 weeks bolus treatment (LAOT -WOB) value to 
the week 52 visit wil l be analysed for each dataset copy using an analysis of covariance 
(ANCOVA) model with randomised treatment as fixed factor and LAOT -WOB value and 
the time point (study day) of this assessment as covariates. The estimated parameters, and 
their variances, from the model will be used to impute missing HbA 1c values for the change 
from LAOT -WOB to the week 52 visit and subsequently the missing HbA 1c value at the 
week 52 visit.  
3. For each of the complete data sets, the primary endpoint will be analysed using an 
ANCOVA model with region and randomised treatment as fixed factors, and baseline HbA 1c 
as a covariate. The estimates and SDs for the 1000 data sets will be pooled to one estimate 
and associated SD using Rubin’s rule.[ADDRESS_1233082] similarly as 
subjects that discontinue randomised treatment or initiate treatment with bolus insulin for more than 
2 weeks.  
The following sensiti vity analysis evaluating the robustness of the assumptions about the missing 
data will be carried out:  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233083] a worse 
outcome in the insulin icodec arm and a better outcome in the insulin glargine arm compared to 
what was imputed in the primary analysis. This is done by [CONTACT_111423] Δi to the 
imputed HbA 1c values before analysi ng the data. The value of Δi will be varied independently in the 
two treatment arms. The non -inferiority margin of 0.3% will be among the Δi values investigated. 
The plausibility of the values of Δi where the conclusion of the primary analysis change will be 
evaluated to assess the robustness of the primary analysis result.   
9.4.3 Secondary endpoints  
[IP_ADDRESS]  Confirmatory secondary endpoint  
The confirmatory secondary endpoint ‘time in target range 3.9 – 10.0 mmol/L (70 -180 mg/dL)’ 
from week 48 to week 52 will be analysed similarly to the primary endpoint specified above 
without inclusion of a baseline covariate.  
The robustness of the assumptions about the missing data will be evaluated by [CONTACT_746] a two -
dimensional tippi[INVESTIGATOR_881844].  
The statistical analysis of the primary endpoint change in HbA 1c from baseline to week 52  described 
for the primary analysis will be evaluated for superiority if the hierarchical testing is not stopped.  
[IP_ADDRESS]  Supportive secondary endpoi nts 
Supportive secondary endpoints will be evaluated in the framework of the primary estimand.  
Efficacy endpoint  
Change in fasting plasma glucose (FPG) from baseline week 0 (V2) to week 52 (V46)  
Missing FPG values at the week 52 visit (regardless of treatm ent completion status)  will be imputed 
from trial  participants who are from the insulin glargine  group, and who have completed and 
adhered to  their randomised insulin treatment without initiation of bolus insulin treatment for more 
than [ADDRESS_1233084] like subjects completing insulin 
glargine  treatment  without initiation of bolus insulin treatment for more tha n 2 weeks a t any time 
prior to the week 52 visit . Specifically, the  imputations and analyses will be carried out as follows:  
• First, one thousand (1000) copi[INVESTIGATOR_111362]. 
• Second , for each dataset copy, an ANCOVA model with a baseline value as a covariate will be 
fitted to FPG values for subjects who completed their randomised treatment without initiation 
of bolus insulin for more than 2 weeks at any time prior to the week 52 visit in the insulin 
glargine group. The estimated mean, and variances, from the model will be used to impute 
missing values in both treatment groups.  
• For each of the complete data sets, the endpoint will be analysed using an AN COVA  model 
with region and randomised treatment as fixed factors, and a baseline value as  a covariate. The 
estimates and SDs for the 1000 data sets will be pooled to one estimate and associated SD 
using  Rubin’s rule20. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  52 of 94 
 
Safety endpoints  
Hypoglycaemic epi[INVESTIGATOR_881845]:  
• Number of severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3) from  baseline  week 0 (V2) to week 52 
(V46) . 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL), 
confirmed by [CONTACT_41132]) from baseline week 0 (V2) to week 52 (V46) . 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL), 
confirmed by [CONTACT_41132]) or severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3) from  baseline  week 0 
(V2) to week 52 (V46) . 
The following hypoglycaemic endpoints will be analysed separately using the method described 
below, substituting the main -on-treatment period with the on -treatment period : 
• Number of severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3), fr om baseline  week 0 (V2) to week 83 
(V63) . 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL) 
confirmed by [CONTACT_41132]), from  baseline  week 0 (V2) to week 83 (V63) . 
• Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 mg/dL), 
confirmed by [CONTACT_41132]) or severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3), from  baseline  week 0 
(V2) to week 83 (V63) . 
For subjects who discontinued their randomised treatment, the number of epi[INVESTIGATOR_684285] (time o f follow -up 2 visit (V63)  to planned end of the main -on-treatment period) will be 
imputed using a multiple imputation technique, assuming that the event rate pre -follow -up 2 visit 
(V63)  follows the respective treatment groups rate whilst post -follow -up 2 visit (V63)  event rate is 
the rate of the comparator group. The imputation will be done as follows:  
1. First, a Bayes negative binomial model with log -link function will be fitted to the event rate 
data to obtain the posterior distribution of model parameters.  The model will include region 
and randomised treatment as fixed factors and the logarithm of the main -on-treatment period 
as offset.   
2. Second, based on the estimated parameters for the comparator group in this model, the 
number of epi[INVESTIGATOR_881846] p eriod will be imputed for subjects who discontinued 
their randomised treatment. Multiple copi[INVESTIGATOR_014] (1000 copi[INVESTIGATOR_014]) of a complete data set will be 
generated by [CONTACT_111424].  
3. For each of the complete data sets, the number of epi[INVESTIGATOR_1841] w ill be analysed using a negative 
binomial model with log -link, fixed factors and offset as described in step 1. The estimates 
and SDs for the 1000 data sets will be pooled to one estimate and associated SD using 
Rubin’s rule20. 
For the definition and classification of hypoglycaemic epi[INVESTIGATOR_111367] 7  (Section 10.7). 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  53 of 94 
 
Mean weekly insulin dose from week 50 (V44) to week 52 (V46)  
Mean weekly insulin dose during the last 2 weeks of treatment (from week 50 to 52) will be log -
transformed and analysed without u sing the baseline value as a covariate, but otherwise using the 
same statistical model as specified for change in FPG.   
Time spent < 3.0 mmol/L (54 mg/dL) and time spent > 10 mmol/L (180 mg/dL) f rom week 48 
(V42) to week 52 (V46)  
Time spent < 3.0 mmol/L (54 mg/dL) (below range) and time spent > 10 mmol/L (180 mg/dL) 
(above range) from week 48 to week 52 will be analysed separately in a similar manner as ‘time in 
target range 3.9 – 10.0 mmol/L (70 -180 mg/dL)’  if deemed appropriate , i.e. if data can be 
considered normally distributed. However, if a large  number  of subjects have 0% time spent, then 
an alternative analysis will be performed either considering the endpoint as a dichotomous endpoint 
or by [CONTACT_2931] a censored analysis of the log -transformed value s. Further details will be provided in 
the SAP . 
Change in body weight from  baseline  week 0 (V2) to week 52 (V46)  
Change in body weight from week [ADDRESS_1233085] safety assessments (SAEs, 
AEs, safety laboratory parameters, vital signs, etc.) will be reported descriptively based on both t he 
main -on-treatment and  the on -treatment period ; including any notable changes of clinical interest in 
laboratory parameters. In addition, SAEs will be reported descriptively based on the in -trial period.  
9.4.6 Other analyses   
For other analyses,  please refer to the SAP.  
[IP_ADDRESS]  Pharmacokinetic modelling  
Not applicable  for this trial.  
9.[ADDRESS_1233086] visit . Subjects will provide consent for the full length of the trial. To preserve trial 
integrity during the extension phase, dissemination of results from the main phase will initially be 
limited to  communication internally and with regulatory authorities.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233087] visit of the main p hase of the trial. The 
results from this main p hase will thereafter be reported. The complete trial will be reported after 
database lock of the extension p hase. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  55 of 94 
 
10 Supporting documentation and operational considerations  
10.1 Appendix 1: Regulatory, ethical, and trial oversight considerations  
10.1.1  Regulatory and ethical considerations  
This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki21 and applicable ICH good clinical practice (GCP) Guideline22. 
• Applicable laws and regulations . 
• The protocol, informed consent form, investigator’s brochure (as applicable) and other relevant 
documents (e.g. advertisements) must be submitted to an IRB/IEC and reviewed and approved 
by [CONTACT_1201]/IEC before the trial is initiated.  
• Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the clinical trial report  according to national requirements.  
• Any amendments to the protocol will requi re IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
safety hazard to trial subjects.  
• Before a site is allowed to start screening subjects, written notification from Novo Nord isk must 
be received.  
• The investigator will be responsible for:  
o providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and procedures established by [CONTACT_5040]/IEC and/or regulatory au thorities  
o notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
o providing oversight of the conduct of the trial at the site and adherence to 
requirements of ICH guidelines22, the IRB/IEC, and all other applicable local 
regulations  
o ensuring submission of the clinical trial report  synopsis to the IRB/IEC  
o reporting any potential serious breaches to the sponsor immediately after discovery . 
10.1.2  Financial disclosure  
Investigators and sub -investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accura te financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.  
10.1.3  Informe d consent process  
• The investigator or his/her representative will explain the nature of the trial to the subject and 
answer all questions regarding the trial.   
• The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.   
• Subjects must be informed that their participation is voluntary.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  56 of 94 
 
• Subjects must be informed about their privacy rights.  
• Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines22, Declaration of Helsinki21 and the IRB/IEC 
or site.  
• The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was obtained. The authorised 
person obtaini ng the informed consent must also sign and date the informed consent form 
before any trial related activity.  
• The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualifi ed person, in accordance with local 
requirements.  
• Subjects must be re -consented to the most current version of the informed consent form (s) 
during their participation in the trial.  
• A copy of the informed consent form (s) must be provided to the subject.  
10.1.[ADDRESS_1233088] may 
receive a “welcome to the trial letter” and a “thank you for your participation letter” after 
completion of the trial. Further, the subject may receive other written information dur ing the trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].  
10.1.5   Data protection  
• Subjects will be assigned a [ADDRESS_1233089] are transferred to Novo Nordisk.  
• The subject and any biological material obtained  from the subject will be identified by [CONTACT_41163], visit number and trial ID. Appropriate measures such as encryption or leaving out 
certain identifiers will be enforced to protect the identity of subjects as required by [CONTACT_5737], 
regional and national r equirements.   
• The subject must be informed about his/her privacy rights, including that his/her personal trial 
related data will be used by [CONTACT_18023]. The 
disclosure of the data must also be explained to the subject.   
• The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, and 
by [CONTACT_6668].  
10.1.6  Committees structure  
[IP_ADDRESS]  Novo Nordisk safety committee  
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by [CONTACT_18025].  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  57 of 94 
 
[IP_ADDRESS]  Trial safety group  
Not applicable for this trial.  
[IP_ADDRESS]  Data monitoring committee  
Not applicable for this trial.  
[IP_ADDRESS]  Event adjudication committee  
An independent external EAC is established to perform ongoing blinded adjudication of selected 
AEs and deaths (see  Table  8-1). 
The EAC will evaluate events sent for adjudication using pre -defined definitions and guidelines in 
accordance with the EAC charter. The evaluation is based on review of pre -defined clinical data 
collected by [CONTACT_30107]. The EAC is composed of permanent members covering all required medical 
specialities. EAC members must disclose any potential conflicts of interest and must be independent 
of Novo Nordisk. The EAC will have no authority to impac t trial conduct, trial protocol or 
amendments. The assessments made by [CONTACT_881865] .  
10.1.7  Dissemination of clinical trial data  
Information of the trial will be disclosed at clinic altrials.gov and novonordisk -trials.com. It will also 
be disclosed according to other applicable requirements, such as those of the International 
Committee of Medical Journal Editors (ICMJE)23, the Food and Drug Administration Amendment 
Act (FDAAA)24, European Commission Requirements1, 25, [ADDRESS_1233090] at 
these web sit es, Novo Nordisk may disclose the investigator’s contact [CONTACT_18026]. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
The primary completion date (PCD) is the last assessment of the primary endpoint, and is for this 
trial last subject first treatment  + [ADDRESS_1233091] completed visit 
V46. The PCD determines the deadline for results disclosure at clinicaltrials.gov according to 
FDAAA.  
10.1.8  Data quality assurance  
[IP_ADDRESS]  Case repo rt forms  
• Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data.  
• All subject data relating to the trial will be recorded on electronic CRFs (eCRFs)  unless 
transmitted electronically to Novo Nord isk (e.g. laboratory and eDiary  data) or when 
applicable on paper CRF. The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
• The following will be provided as paper CRFs:  
o Pregnancy forms  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  58 of 94 
 
• The following will be provided as paper CRFs to be used when access to the eCRF is revoked 
or the eCRF is temporarily unavailable:  
o Adverse event  forms   
o Safety information forms  
o Technical complaint forms (also to be used to report complaints on trial product not 
yet allocated to a subject)  
• Corrections to the CRF data may be made by [CONTACT_36322]’s delegated 
staff. An audit trail will be maintained in the CR F application containing as a minimum: the 
old and the new data, identification of the person entering the data, date and time of the entry 
and reason for the correction. If corrections are made by [CONTACT_093]’s delegated staff after 
the date when the  investigator signed the CRF, the CRF must be signed and dated again by [CONTACT_1275].  
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it wi ll be available to Novo 
Nordisk for data verification and validation purposes.   
[IP_ADDRESS]  Monitoring  
• The investigator must permit trial -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents ( original documents, 
data and records). Direct access includes permission to examine, analyse, verify and reproduce 
any record(s) and report(s) that are important to the evaluation of the trial. If the electronic 
medical record does not have a visible audit  trail, the investigator must provide the monitor 
with signed and dated printouts. In addition, the relevant site staff should be available for 
discussions at monitoring visits and between monitoring visits (e.g. by [CONTACT_756]).   
• Trial monitors will perform  ongoing source data verification to confirm that data entered into 
the eCRF  by [CONTACT_18029], complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountabilit y and collect completed paper CRF pages, if applicable, and that the trial is being 
conducted in accordance with the currently approved protocol and any other trial agreements, 
ICH, GCP, and all applicable regulatory requirements.  
• Monitoring will be conduc ted using a risk -based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by [CONTACT_3454]) and 
visits to sites.   
• Monitors will review the subject’s medical records and other source data  to ensure consist ency 
and/or identify omissions compared to the eCRF.  
[IP_ADDRESS]  Protocol compliance  
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor without delay and the implications of the deviation must be reviewed and 
discussed.  
Deviations must be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233092] be verifiable in source documentation, except for the following  
data that has been transferred directly into the database and will be considered source data:  
• For e.g. eDiary, data in the service providers’ database is considered source data.  
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the site.  
• Data reported o n the paper CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents, or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer records. 
Also,  current medical records must be available.   
• It must be possible to verify subject’s medical history in source documents, such as subject’s 
medical record.  
• The investigator must document any attempt to obtain external medical information by [CONTACT_881866] e(s) when information was requested, and who was contact[INVESTIGATOR_530].  
• Definition of what constitutes source data can be found in a source document agreement at each 
site. There will only be one source document defined at any time for any data element.  
10.1.10  Retention of clinical trial documentation  
• Records and documents, including signed informed consent forms, pertaining to the conduct of 
this trial must be retained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies req uire a longer retention period. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records may be transferred to another location or party without written notification to Novo 
Nordisk.   
• The investigator  must be able to access his/her trial documents without involving Novo Nordisk 
in any way. If applicable, electronic CRF (eCRF) and other subject data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems  supplied 
by [CONTACT_3454]. Site -specific CRFs and other subject data (in an electronic readable format 
or as paper copi[INVESTIGATOR_17951]) must be retained by [CONTACT_779]. A copy of all data will be stored by 
[CONTACT_3454].  
• Subject’s medical records must be kept  for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
10.1.[ADDRESS_1233093] 
inform the subjects promptly and ensure appropriate therapy and follow -up. The investigator and/or 
Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation.  
Sites will be closed upon trial completion. A site is considered closed when all required documents 
and trial supplies have been collected and a site closure visit has been performed.  
The investigator may initiate site closure at any t ime, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  60 of 94 
 
Reasons for the early closure of a site by [CONTACT_41177]:  
• failure of the investigator to comply  with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines  
• inadequate recruitment of subjects by [CONTACT_093]  
• discontinuation of further trial product development.  
10.1.[ADDRESS_1233094] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to whom he/she has delegated specified trial -
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of th e trial and to protect the rights, safety, and well -being of the subjects.   
A qualified physician, who is an investigator or a sub -investigator for the trial, must be responsible 
for all trial -related medical decisions.   
The investigator is responsible for  filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identificati on 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.   
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.  
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects dur ing that time.  
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.   
The investigator and other site personnel must have sufficie nt English skills according to their 
assigned task(s).  
10.1.[ADDRESS_1233095] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unle ss others have shown 
negligence.   
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by [CONTACT_18033].   
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233096], if deemed necessary by [CONTACT_3454]. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordi sk may publish on its clinical trials website a redacted clinical trial report  for this trial.  
One or two investigators will be appointed by [CONTACT_36345]  (signatory investigator) on behalf of all participating i nvestigators.  
[IP_ADDRESS]  Communication of results  
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in a peer -reviewed scientific journal, abstract 
submission with a poster or ora l presentation at a scientific meeting or disclosure by [CONTACT_11174].  
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the rele ase of data 
until specified milestones are reached, for example when the clinical trial report  is available. This 
includes the right not to release the results of interim analyses, because the release of such 
information may influence the results of the en tire trial.  
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_1233097] inte llectual property.  
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
content of any publication, both the in vestigators’ and Novo Nordisk opi[INVESTIGATOR_17952].  
[IP_ADDRESS]  Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, an alysis or interpretation of data to report the results in one 
or more publications.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233098], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_881867].27 
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication.   
Where required by [CONTACT_18038], the investigator from each site will be named in an 
acknowledge ment or in the supplementary material, as specified by [CONTACT_18038].   
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, analyses based on single -site data usually have significant statistical 
limitations and frequently do not  provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscr ipt 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial.  
[IP_ADDRESS]  Investigator access to data and review of results  
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database.  
Individual investigators will have their own research subjects’ data and will be provided with the 
randomisation code after results are avail able.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID:  NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  63 of 94 
 
10.2 Appendix 2: Clinical laboratory tests  
• The tests detailed in Table  10-1 and Table  10-2 will be performed by [CONTACT_2237].  
• Additional tests may be perfo rmed at any time during the trial as determined necessary by [CONTACT_41161]. Only laboratory samples specified in the protocol 
should be sent to the central laboratory for analysis; if additional laboratory sampling is 
needed, e.g. to follow -up on AEs, this must be done at a local laboratory.  
• The central lab will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by [CONTACT_111428]/or their processes 
according to their lab standard operating procedure s (SOPs ). These data will not be transferred 
to the trial database. The investigator should review such values for AEs and report these 
according to this protocol.  
• The investigator must review all laboratory r esults for concomitant illnesses and AEs.  
• Laboratory samples will be destroyed no later than at finalisation of the clinical trial report , 
except the following:  
• For haematology samples (differential count) where the test result is not normal, then a part 
of the sample may be kept for up to two years or according to local regulations.   
• Human biosamples for retention will be stored as described in Appendix  6 (Section 10.6). 
Table  10-1 Protocol -required efficacy laboratory assessments  
Laboratory 
assessments  Parameters  
Glucose metabolism   • Fasting plasma glucose  (FPG)1 (V2, V12, V20, V28, V46, V61)  
• HbA 1c (V1, V2, V12, V20, V28, V36, V40 , V46 , V51, V55, V61,  V46A,  V61A ) 
NOTE:  
1An FPG result < 3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a 
hypoglycaemic  epi[INVESTIGATOR_111369] ( Appendix 3 , Section 10.3). 
A FPG result >16.7 mmol/L (300 mg/dL) should not be reported as a hyperglycaemic epi[INVESTIGATOR_111370] (Appendix  3, Section 10.3). 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID:  NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  64 of 94 
 
Table  10-2 Protocol -required safety laboratory assessments  
Laboratory  
 assessments  Parameters  
Haematology  
(V1, V12, V28, V3 6, 
V46, V5 1, V61)  • Erythrocytes  
• Haematocrit  
• Haemoglobin  
• Leucocytes  
• Thrombocytes  
• Basophils   
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  
Biochemistry1  
(V1, V12, V28, V3 6, 
V46, V5 1, V61)  • Alanine  Aminotr ansferase  
• Albumin  
• Alkaline phosphatase  
• Aspartate Aminotransferase  
• Creatinine  
• Potassium  
• Sodium  
• Total bilirubin  
Lipi[INVESTIGATOR_805]  
(V2, V12, V28, V3 6, 
V46, V5 1, V61)  • Cholesterol  
• High density lipoprotein (HDL) cholesterol  
• Low density lipoprotein (LDL) cholesterol  
• Triglycerides  
• Free fatty acids  
Pregnancy Testing  
(V2, V46, V61, V63)  • Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for wom an of childbearing potential)2 
Other tests  • eGFR calculated by [CONTACT_41162] -EPI [INVESTIGATOR_10908], eGFR is for screening purposes only  
• In case of systemic hypersensitivity (Section 8.9.2 ): Tryptase (optimal 0.[ADDRESS_1233099] the hypersensitivity reaction), total IgE antibodies, anti -insulin icodec IgE 
antibodies, anti -insulin icodec binding antibodies, anti -human insulin IgE an tibodies.  
Notes:  
1Details of required actions for increased liver parameters  are given in Section 10.3 (Hy’s Law).  
2Local urine testing will be standard unless serum testing is required by [CONTACT_18039]/IEC.  
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  65 of 94 
 
10.3 Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, 
follow -up, and reporting  
10.3.[ADDRESS_1233100] (IMP), whether or not considered related to 
the IMP.  
An AE can therefore be any unfavourable  and unintended sign, including an abnormal laboratory 
finding, symptom or disease (new or exacerbated) temporally associated with the use of an IMP.  
 
Events meeting  the AE definition  
• Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened 
from prior to the time point from which AEs are collected . 
• Conditio ns detected or diagnosed after IMP administration even though it may have been 
present prior to the time point from which AEs are collected .  
• Exacerbation/worsening of a chronic or intermittent condition including either an increase in 
frequency and/or int ensity of the condition . 
• Signs, symptoms or the clinical sequelae of a suspected drug -drug interaction . 
• Signs, symptoms  or the clinical sequelae of a suspected overdose of IMP regardless of intent . 
A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as 
an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fu lfil the definition.  
Events NOT  meeting the AE definition  
• Conditions present prior to the time point from which AEs are collected and anticipated day -to-
day fluctuations of these conditions, including those identified during screening or other trial 
procedures performed before exposure to IMP.  
• Note: Conditions present or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history.  
• Medical or surgical procedures (e.g. endoscopy, appendectomy). The condition that leads to the 
procedure is the AE.  
• Medical  or surgical procedures not preceded by [CONTACT_18040] a known condition.  
10.3.[ADDRESS_1233101] one of the following criteria:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death, if it were mo re severe.  
c. Requires inpatient hospi[INVESTIGATOR_15574]  
• Hospi[INVESTIGATOR_17953]/or treatment that would not have been appropriate in the physician’s office 
or outpatient setting. Complications that occur during hospi[INVESTIGATOR_492256]. If a complication 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  66 of 94 
 
prolongs hospi[INVESTIGATOR_17955], the event is serious. When in 
doubt as to whether “hospi[INVESTIGATOR_11956]” occurred or was necessary, the AE should be considered 
serious.  
• Hospi[INVESTIGATOR_881847] (e.g. elective medical or surgical procedures) of a 
condition that was present prior to the time point from which AEs are collected, and that did 
not worsen, is not considered an AE.  
Note:  
• Hospi[INVESTIGATOR_17957], trial rela ted, social and convenience reasons do not 
constitute AEs and should therefore not be reported as AEs or SAEs.   
• Hospi[INVESTIGATOR_881848], planned before trial inclusion, are not 
considered AEs or SAEs.  
d. Results in persiste nt or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not intended to include experience of relatively minor medical significance, 
such as uncom plicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma 
(e.g. sprained ankle), which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Important medical event:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations. This includes important medical events that may not be 
immediately life -threatening or result in death or hos pi[INVESTIGATOR_881849]. These events should usually be considered serious and reported as SAEs 
using the important medi cal event criterion.  
• The following adverse events must always be reported as SAEs using the important medical 
event criterion if no other seriousness criteria are applicable:  
• Suspi[INVESTIGATOR_17960]  
• Risk of liver injury d efined as alanine aminotransferase or aspartate aminotransferase 
>3 x UNL and total bilirubin >2 x UNL where no alternative aetiology exists (Hy's law)  
 
10.3.3  Description of event(s) for adjudication and AEs requiring additional data 
collection  
Description of event(s) for adjudication and AEs requiring additional data collection (on 
specific event form)  
Events for adjudication  
An event for adjudication is a selected AE or death evaluated by [CONTACT_111420] 
a blinded manner, pleas e refer to Table  8-1 Appendix 1  (Section [IP_ADDRESS] ) and Figure  10-1. 
• Death  
• All cause death  
• Acute coronary syndrome  
• All types of acute myocardial infarction and unstable angina pectoris requiring 
hospi[INVESTIGATOR_11956]  
• Cerebrovascular event (stroke or transient ischemic attack)  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  67 of 94 
 
• Epi[INVESTIGATOR_364052], spi[INVESTIGATOR_36232], or retinal vascular injury as a result of haemorrhage or ischemia, with or without 
infarction  
• Heart failure (requiring hospi[INVESTIGATOR_111347])  
• New epi[INVESTIGATOR_111374], unscheduled 
hospi[INVESTIGATOR_111375]/office/emergency department visit  
Adverse events requiring additional data collection  
AEs requiring additional data collection on a specific event form.  
 
Injection site reaction  
If an event of injection site reaction is observed , additional information must be obtained if 
available on a separate  form . 
Hypersensit ivity  
Systemic hypersensitivity can be manifested as isolated symptoms such as urticaria, angioedema, 
conjunctivitis, rhinitis, bronchospasm, gastrointestinal symptoms (nausea, vomiting, diarrhea, 
abdominal pain), or as anaphylaxis or anaphylactic shock.  
Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden 
release of mast cell - and basophil -derived mediators into the circulation28. It most often results 
from immunologic reactions to foods, medications, and insect stings, although it can also be 
induced through nonimmunologic mechanisms by [CONTACT_111429] a sudden, 
systemic degranulation of mast cells or basophils29. Characteristic symptoms and si gns, occurring 
minutes to a few hours after exposure to potential triggering agents or events may include: 
flushing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, 
shortness of breath, abdominal pain, vomiting, and/or hyp otension, dizziness or collapse.  
Local hypersensitivity reactions, including rash, redness, pruritus and oedema, may occur at the 
site of investigational drug injection.  
Drug hypersensitivity reactions (DHRs) are the adverse effects of pharmaceutical formu lations 
(including active drugs and excipi[INVESTIGATOR_840]) that clinically resemble allergy30. They can be allergic and 
non-allergic.  
If a hypersensitivity event is suspected, the subjects must contact [CONTACT_881868]. All events must be reported, and in case of systemic hypersensitivity, 
additional  information must be provided  on a separate  form . 
Medication error  
A medication error is an unintended failure in the IMP treatment process that leads to, or has the 
potential to lead to, harm to the subject, such as:   
• administration of wrong drug.   
Note: Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug.  
• wrong route of administration, such as intramuscular instead of subcutaneous . 
• accidental administration of a lower or  higher dose than intended. The administered dose must 
deviate from the intended dose to an extent where clinical consequences for the trial subject 
were likely to happen as judg ed by [CONTACT_093], although they did not necessarily occur.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  68 of 94 
 
• missed doses or drug pauses are not to be reported as a medication error.  
Misuse and abuse   
• Situations where the IMP is intentionally and inappropriately used not in accordance with the 
proto col (e.g. overdose to maximise effect ). 
• Persistent or sporadic, intentional excessive use of an IMP which is accompanied by [CONTACT_18041] (e.g. overdose with the intention to cause harm) . 
Medication error, misuse and abuse must always be reported as an AE (e.g. accidental overdose, 
intentional overdose or other) on a separate AE form, and a medication error, misuse and abuse 
form must be completed. In case of a medication error and/or misuse and abuse resulting in a 
clinical cons equence, this must be reported on an additional AE form.  
 
10.3.4  Recording and follow -up of AE and/or SAE  
AE and SAE recording  
• The investigator will record all relevant AE/SAE information in the CRF.  
• The investigator will attempt to establish a diagnosis of the  event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documen tation (e.g. hospi[INVESTIGATOR_1088], laboratory and diagnostics reports) related to the 
event.  
• There may be instances when copi[INVESTIGATOR_14168] (e.g. medical records) for certain 
cases are requested by [CONTACT_3454]. In such cases, all subject identi fiers, with the exception 
of the subject number, will be redacted on the copi[INVESTIGATOR_636134].  
• For all non -serious AEs, the applicable forms should be signed when the event is resolved or at 
the end of the trial at the latest. For sign -off of SAE related forms, refer to “AE and SAE 
reporting via paper CRF” later in this section.  
• Novo Nordisk products used as concomitant medication or NIMP: if an AE is considered to 
have a causal relationship with a Novo Nordisk ma rketed product used as or NIMP or 
concomitant medication in the trial, it is important that the suspected relationship is reported to 
Novo Nordisk, e.g. in the alternative aetiology section on the safety information form. Novo  
Nordisk may need to report th is adverse event to relevant regulatory authorities . 
 
Assessment of severity  
The investigator will assess severity for each event reported during the trial and assign it to one of 
the following categories:   
• Mild : An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate : An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe : An event that prevents normal everyday activities.  
Note: An AE t hat is assessed as severe should not be confused with a SAE. Both AEs and 
SAEs can be assessed as severe.  
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  69 of 94 
 
Assessment of causality  
• The investigator is obligated to assess the relationship between IMP and the occurrence of each 
AE/SAE.  
• Relationship between an AE/SAE and the relevant IMP(s) should be assessed as:  
• Probable - Good reason and sufficient documentation to assume a causal relationship.  
• Possible - A causal relationship is conceivable and cannot be dismissed.  
• Unlikely - The event is most likely related to aetiology other than the IMP.  
• Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk 
factors, as well as the temporal relationship of the event to IMP administration, will be 
considered and investigat ed. 
• The investigator should use the Investigator’s Brochures for insulin icodec, and the summary 
of product characteristics for non -Novo Nordisk marketed products, for the assessment. For 
each AE/SAE, the investigator must document in the medical records t hat he/she has reviewed 
the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report. However, it is important that the investiga tor 
always makes an assessment of causality for every event before the initial transmission of 
the SAE data . 
• The investigator may change his/her opi[INVESTIGATOR_17963], in light of follow -up information, 
and update the causality assessment in the CRF.  
• The ca usality assessment is one of the criteria used when determining regulatory reporting 
requirements . 
Final outcome  
The investigator will select the most appropriate outcome:  
• Recovered/resolved : The subject has fully recovered, or by [CONTACT_18043] . 
• Recovering/resolving : The condition is improving, and the subject is expected to recover from 
the event. This term may be applicable in cases of chronic conditions, cancer or  AEs ongoing 
at time of death (where death is due to another AE).  
• Note: For SAEs, this term is only applicable if the subject has completed the follow -up period 
and is expected to recover.  
• Recovered/resolved with sequelae : The subject has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE.  
• Not recovered/not resolved : The condition of the subject has not improved, and the symptoms 
are unchanged, or the outcome is not known.  
Note: This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE).  
• Fatal : This term is only applicable if the subject died from a condition r elated to the reported 
AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as 
“recovered/resolved”, “recovering/resolving”, “recovered/resolved with sequelae” or “not 
recovered/not resolved”. An AE with a fatal outcome mus t be reported as an SAE.  
• Unknown : This  term is only applicable if the subject is lost to follow -up. 
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233102] of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_18044]/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). 
This may include additional laboratory tests (e.g. skin prick test) or investigations, 
histopathological examinations, or consultation with other health care professionals.  
If a subject dies during participation in the t rial or during a recognised  follow -up period, Novo 
Nordisk may request a copy of the autopsy report including histopathology.  
New or updated information will be recorded in the CRF.  
 
10.3.5  Reporting of SAEs  
SAE reporting via electronic CRF  
• Relevant forms (AE and safety information form) must be completed in the CRF.  
• For reporting and sign -off time lines, see Figure  10-1. 
• If the CRF is unava ilable for more than 24 hours, then the site will use the paper AE form, and 
if the CRF is unavailable for more than 5 calendar days, then the site will use the paper safety 
information form (see box below).  
• The site will enter the SAE data into the CRF as  soon as it becomes available.  
• After the trial is completed, the trial database will be locked, and the CRF will be 
decommissioned to prevent the entry of new data or changes to existing data. If a site receives 
a report of a new SAE from a subject or receives updated data on a previously reported SAE 
after CRF decommission, then the site can report this information on a paper AE and safety  
information form (see box below) or to Novo Nordisk  by [CONTACT_756].  
 
AE and SAE reporting via paper CRF  
• Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk in 
accordance with Section 10.1.5 . 
• For SAEs, initial notification via telephone is acceptable, although it does not replace the need 
for the investigator to complete the AE and safety information form within the designated 
reporting timelines (as illustrated in  figure  Figure 10-1): 
• AE form within 24 hours  
• Safety information form within 5 calendar days  
• Both forms must be signed within [ADDRESS_1233103] knowledge by [CONTACT_1275].  
• The specific event form for AEs requiring additional data collection within 14  calendar days .  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233104] details for SAE reporting can be found in the investigator trial master file.  
Reporting of AEs for non -Novo Nordisk medical devices provided by [CONTACT_881869] G6:  
All complaints (including AEs) should be reported directly to the manufacturer .  
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  72 of 94 
 
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information  
Definitions  
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.  If fertility is unclear and a menstrual cycle cannot be confirmed before first 
dose of trial treatment, additional evaluation should be considered.  
Females in the following categories are not co nsidered WOCBP  
1. Premenarcheal  
2. Females with one or more of the following:  
• Documented total hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Females with permanent infertility due to an alternate medical cause other than the a bove (e.g. 
Müllerian agenesis, androgen insensitivity), investigator discretion should be applied in determining 
trial enrolment.  
3. Postmenopausal female:  
• A postmenopausal state is defined as amenorrhoea for 12 months without an alternative medical 
cause.  
• Females  ≥ 50 years of age can be considered postmenopausal (irrespective of treatment with a 
hormonal contraception or hormone replacement therapy (HRT)) if they have both:  
o Amenorrhoea and  
o documentation of 2 high follicle stimulating hormone (FSH) measurements in the 
postmenopausal range and one of these was observed ≥1 year prior to screening.  
• Females ≥ [ADDRESS_1233105] an  acceptable effective contraception methods  as described in 
Table  10-3. 
Note: Documentation regarding categories 1-3 can come from the site staff’s review of subject’s 
medical records, medical examination or medical history interview.  
Contraception guidance  
Male subjects   
No contraception measures are required as the risk of teratogenicity/fetotoxicity caused by [CONTACT_881870]31. 
Female subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use at least an 
acceptable effective methods of contraception consistently and correctly as described in Table  10-3. 
As a minimum, contraception should be maintained until treatment discontinuation . 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  73 of 94 
 
Table  10-3 Acceptable contraceptive methods  
CONTRACEPTIVESa ALLOWED DURING THE TRIAL INCLUDE:  
ACCEPTABLE METHODSb 
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action  
• Male or female condom with or without spermicidec 
• Cervical cap, diaphragm, or sponge with spermicide  
• A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).  
NOTES  
a) Contraceptive use by [CONTACT_881871].  
b) Considered effective, but not highly effective - failure rate of ≥1% per year. Periodic 
abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactat ional amenorrhoea method (LAM) are not acceptable methods of 
contraception.  
c) Male condom and female condom should not be used together (due to risk of failure with 
friction).  
 
Pregnancy testing  
• Additional pregnancy testing should be performed during the treatment period, if required 
locally . Please  refer to the Appendix 9  (Section 10.9). 
• WOCBP should only be included after a negative highly sensitive urine pregnancy test (refer to 
Appendix 2 , Section 10.2). 
• As a minimum,  pregnancy test should be performed at the end of relevant systemic exposure 
(refer to Appendix 2  (Section 10.2) and the trial flowchart  (Section 1.2). 
• Pregnancy testing should be performed whenever a menstruation is missed or when pregnancy 
is otherwise suspected.  
Collection of pregnancy information   
Female subjects who become pregnant  
• Investigator will collect pregnancy information on any female subject who becomes pregnant 
while participating in this trial.  
• Information will be recorded on the appropriate form and submitted to Novo Nordisk within [ADDRESS_1233106] ’s pregnancy (see Figure  10-2). 
• Subject will be followed to determine the outcome of the pregnancy. The investigators will 
collect follow -up information on subject and neonate which will be forwarded to Novo 
Nordisk within  14 calendar days. Generally, follow -up will not be required for longer than 1 
month beyond the delivery date.  
• Any termination of pregnancy will be reported. regardless of the foetal status (presence or 
absence of anomalies) or indication for procedure.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  74 of 94 
 
• While pregnancy itself is not considered to be an AE or SAE, any adverse event in connection 
with pregnancy or elective termination of a pregnancy for medical reasons will be reported as 
an AE or SAE. If relevant, consider adding “gestational”, “pregnancy re lated” or similar term 
when reporting the AE/SAE.  
• Pregnancy outcome should be documented in the subject’s medical record. Abnormal 
pregnancy outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies 
and ectopic pregnancy) is consid ered an SAE.  
• Any SAE occurring as a result of a post -trial pregnancy which is considered possible/probably 
related to the IMP by [CONTACT_111433] 3  (Section 10.3) . While the investigator is not obligated to actively seek this 
information in former subjects, he /she may learn of an SAE through spontaneous reporting.  
 
Maternal form 1b  
  14 calendar days after birthMaternal form 1a
  14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2   14 calendar days
Paternal form*1   14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
Figure  10-[ADDRESS_1233107] who becomes pregnant while participating i n the trial will discontinue IMP .  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  75 of 94 
 
10.5 Appendix 5: Technical complaints: Definition and procedures for recording, 
evaluation, follow -up and reporting  
10.5.1  Definition of technical complaint  
Technical complaint definition  
• A technical complaint  is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but 
does not concern the AE itself.  
Examples of technical complaints:  
• Problems wit h the physical or chemical appearance of trial products (e.g. discoloration, 
particles or contamination)  
• Problems with packaging material including labelling  
• Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen -injector and the needle) . 
Time period for detecting technical complaints  
All technical complaints  which occur from the time of receipt of the product at site until the time 
of the last usage of the product must be collected for products predefined on the technical 
complaint form.  
 
10.5.[ADDRESS_1233108] be reported on a separate technical complaint form:  
1. One technical complaint form must be completed for each affected DUN.  
2. If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed.  
 
Timelines for reporting of technical complaints to Novo Nordisk  
The investigator must complete the technical complaint form in the CRF within:  
• 24 hours if related to an SAE  
• [ADDRESS_1233109] enter the information on the technical complaint 
form in the CRF.  
 
Follow -up of technical complaints  
The investigator is responsible for ensuring that new or updated information will be recorded on 
the originally completed form.  
 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233110]. 
 
10.5.3  Reporting of technical complaints  
Reporting of technical complaints for Novo Nordisk products not included in technical 
complaint form  
Technical complaints on Novo Nordisk products not included in the technical complaint form 
should be reported to local Novo Nordisk . 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  77 of 94 
 
10.6 Appendix 6: Retention of human biosamples  
Hypersensitivity reaction samples  
In case of a systematic hypersensitivity reaction, the additional blood samples taken in relation to 
the reaction (section 8.9.2 ) may be retained to follow -up on the hypersensitivity reaction. If deemed 
relevant by [CONTACT_3454], relevant exploratory tests may be performed, e.g. histamine release 
(basophil activation). I f measured, such data will be reported in a separate report . 
The samples will be stored at Novo Nordisk or a Novo Nordisk designated referral central bio -
repository. The samples might be transferred to other countries, if not prohibited by [CONTACT_21482] s. Only Novo Nordisk staff and bio -repository personnel will have access to the stored 
samples.  The samples may be shipped to a contract research organisation (CRO) for analysis.  
The samples will be anonymised (identified only by a unique sample ID, visit number, trial 
identification number and sampling date). Confidentiality and personal data protection will be 
ensured during storage after the end of trial and no direct identification of the subject  will be stored 
together with the samples.  
Potential furt her analyses of the samples will not have any consequences for the subject and their 
relatives. Subjects can contact [CONTACT_111434].  
The samples w ill be stored after end of trial and until marketing authorisation approval or until the 
research project terminates, but no longer than 15 years from end of trial after which they will be 
destroyed.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  78 of 94 
 
10.7 Appendix 7: Hypoglycaemic epi[INVESTIGATOR_364054]  10-4 Classification of hypoglycaemia  
Classification of hypoglycaemia  
Level  Glycaemic criteria  Description  
Hypoglycaemia alert value 
(level 1)  < 3.9 mmol/L (70 mg/dL) and  
≥ 3.0 mmol/L (54 mg/dL)  Sufficiently low for treatment with fast -acting 
carbohydrate and dose adjustment of glucose -lowering 
therapy  
Clinically significant 
hypoglycaemia (level 2)  < 3.0 mmol/L (54 mg/dL)  Sufficiently low to indicate serious, clinically important 
hypoglycaemia  
Severe hypoglycaemia 
(level 3)  No specific glucose threshold  1Hypoglycaemia associated with severe cognitive 
impairment requiring external assistance for recovery  
Notes: The Novo Nordisk terms are adapted from IHSG32, ADA33, ISPAD34, type 1 diabetes outcomes program35, 
ATTD19. Severe hypoglycaemia as defined by [CONTACT_41186]36 and ISPAD34. 
 
Severe hypoglycaemia  
1Severe hypoglycaemia is an event requiring assistance of another person to actively administer 
carbohydrates, glucagon, or take other corrective actions. Plasma glucose (PG)  concentrations may 
not be available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low PG concentration36. 
In case of recurrent severe hypoglycaemia, the treatment of the subject is the respo nsibility of the 
investigator and the titration guidelines can be overruled at his/her discretion33.  
Nocturnal hypoglycaemia  
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_111378] 00:01 and 05:59 both inclusive.  
Reporting of hypoglycaemic epi[INVESTIGATOR_881850].  
The following should be reported in the eDiary as hypoglycaemic events:  
- PG values < 3.9 mmol/L (70 mg/dL)  
- Severe hypoglycaemic epi[INVESTIGATOR_881851]. Confirmation of the 
hypoglycaemic epi[INVESTIGATOR_111382]. In case a subject is not able 
to fill in the eDiary (e.g. in case of hospi[INVESTIGATOR_11956]) at time of epi[INVESTIGATOR_1865], the subject can report the 
epi[INVESTIGATOR_111383].  
If the hypoglycaemic epi[INVESTIGATOR_881852], an eCRF AE form and a safety information form must also be filled in. One AE  form 
and safety information form can cover several hypoglycaemic values , if the subject has not 
recovered between the m and has reported them as one  epi[INVESTIGATOR_881853].  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233111] is recommended to measure PG every  15 
minutes until the PG value is ≥ 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance with current guidelines36. 
Repeated low PG measurements can be reported by [CONTACT_111436][INVESTIGATOR_41106] 
a succeeding PG value is ≥ 3.9 mmol/L (70 mg/dL). In case of sever al low PG values within the 
hypoglycaemic epi[INVESTIGATOR_1865], the lowest value is the one that will be reported as the PG value for the 
hypoglycaemic epi[INVESTIGATOR_1865], but the start time of the epi[INVESTIGATOR_364055]. The remaining values w ill be kept as source data.  
If the severity of a hypoglycaemic epi[INVESTIGATOR_111385], only one hypoglycaemic epi[INVESTIGATOR_111386], reflecting the most severe degree of hypoglycaemia.  
Regarding the question: “To feel better, did you need help to get a sugary drink, food, or 
medicine?” the investigator must instruct the subjects to answer “Yes”, if the epi[INVESTIGATOR_111387], glucagon, or take 
other corrective actions. PG concentration s may not be available during an event, but neurological 
recovery following the return of PG to normal is considered sufficient evidence that the event was 
induced by a low PG concentration36.  
eDiary  review  
At each contact [CONTACT_881872][INVESTIGATOR_1841]. In case of incomplete or incorrect data in the eDiary, the subject must 
be questioned whether there have been any severe hypoglycaemic epi[INVESTIGATOR_111388]. The 
subject shall update the reported data in the e Diary accordingly.  
Re-training of subjects  
The subject must be re -trained in how to report hypoglycaemic epi[INVESTIGATOR_111389]. The training should be documented by [CONTACT_111438].  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  80 of 94 
 
10.8 Appendix 8: Titration guideline  
Introduction  
Titration guidelines have been developed, providing recommended dose adjustments at different PG 
levels to ensure that subjects receive an optimal treatment. However, it is recognise d that insulin 
treatment should be individualised, and the specific titration algorithms may not be applicable in 
certain clinical situations. Hence, it is important that other information, such as symptoms of 
hypo -/hyperglycaemia, previous response to dos e adjustments, other glucose measurements and 
other indicators of the subject’s level of glycaemic control, is taken into consideration when 
decisions on dosing are made. The investigator is responsible for the treatment of the subjects and 
can therefore o verrule the guidelines to avoid safety hazards.  
Initiation of trial products  
At randomisation eligible subjects will be randomised to receive insulin icodec or insulin glargine.  
• Insulin icodec  should be taken once weekly on the same day of the week. The st arting dose will 
be 70U.  
• Insulin glargine  should be taken once daily , at anytime of the day but at  the same time every 
day. The starting dose will be 10U.  
• The treat -to-target approach will be applied to optimise glycaemic control throughout the trial.  
• Ther e are no maximum or minimum insulin doses.  
Dose adjustment of trial products during the trial  
After randomisation the investigator should adjust the trial products once weekly or every other 
week in connection with the scheduled visits/phone contacts as de scribed below:  
• The dose adjustment will be based on the three pre -breakfast SMPG values measured on two 
days prior to titration and on the day of the contact.  
• If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s).  
• The prescribed dose should be determined by [CONTACT_111439].  
Titration of insulin  glargine  
Adjustment of insulin glargine will be done in accordance with Table  10-5. 
Table  10-[ADDRESS_1233112] SMPG  Dose adjustment  
Value to use  mmol/L  mg/dL  U 
Lowest of the SMPG 
values  <4.4 <80 –3 
Mean of the SMPG 
values  4.4–7.2 80–130 0 
>7.2 >130  +3 
Titration of insulin icodec  
Adjustment of insulin icodec will be done in accordance with Table  10-6. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233113] SMPG  Dose adjustment  
Value to use  mmol/L  mg/dL  U 
Lowest of the SMPG 
values  <4.4 <80 –20 
Mean of the SMPG 
values  4.4–7.2 80–130 0 
>7.2 >130  +[ADDRESS_1233114] insulin doses is based on all relevant information. A reason for deviating from the algorithm 
should be entered into the HCP web portal by [CONTACT_41192].  
Missing insulin icodec dose guidance  
If an insulin icodec dose is missed for ≤ [ADDRESS_1233115] 
the planned  dose as soon as possible and perform control SMPG measurement. If the missing dose 
is missed for > [ADDRESS_1233116] should await the next planned day -of-injection.  
Dose recommendation from end of treatment and during follow -up (insulin icodec)  
If it is decided that the individual subject should continue basal insulin after end of treatment, it is 
recommended that the subject is switched from insulin icodec to any available basal insulin at the 
discretion of the investigator. The investigator sho uld instruct the subject in how to switch at the 
end of treatment visit (V61).  
Regarding the switch from insulin icodec to post -trial basal insulin the following should be 
considered:  
• Calculate the new daily basal insulin dose dividing the latest insulin  icodec dose by 7  
• Initiate the new daily basal insulin  two weeks  after the last injection of insulin icodec  
• Continue to measure pre -breakfast SMPG daily in the follow -up period. If pre -breakfast SMPG 
exceeds 10.0 mmol/L (180 mg/dL), it should be considered  to initiate the daily basal insulin 
dose earlier than two weeks after the last dose of insulin icodec  
• Consider titrating the basal insulin once or twice weekly according to the pre -breakfast SMPG 
values and the local label of the chosen insulin.  
Data coll ection  
The subject should be instructed to report the following in the eDiary:  
• Date, dose and time of insulin glargine or insulin icodec injections . 
• SMPG values with an indication of “pre-breakfast ” or “other ” (see Section 8.1.1 ). 
• Hypoglycaemic epi[INVESTIGATOR_111390] 7  (Section 10.7). 
 
While using the HCP web portal for titration the following will be entered by [CONTACT_1697]:  
• Insulin glargine or insulin icodec doses prescribed at this contact.  
• Reasons for deviation from the titration algorithm, if applicable.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233117]’s next 
site visit/phone contact. The aim is to  reduce the time periods in which a subject may receive 
suboptimal treatment.  
The titration data should be reviewed by [CONTACT_41194] 24 hours (on workdays). The 
reviewer may contact [CONTACT_41195] e -mail or phone to clarify reasons for deviation  or to 
request entry of missing data. When the investigator receives an inquiry, a response should be 
received at Novo Nordisk within 24 hours (on workdays).  
In addition, Novo Nordisk will monitor changes in HbA 1c. Novo Nordisk may visit or phone sites to 
discuss progress in glycaemic control and titration of individual subjects.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  83 of 94 
 
10.9 Appendix 9: Country -specific requirements  
For Italy : 
• Additional exclusion criteri a:  
o 18. Known hypoglycaemic unawareness as indicated by [CONTACT_222666]’s questionnaire , question [ADDRESS_1233118] to exclusion criteria 18 , information on hypoglycaemia unawareness will be 
recorded according to Clarke ’s questionnaire, question [ADDRESS_1233119]: “To what  extent can you tell by [CONTACT_881873]? ” Subjects answering “never, rarely or sometimes ” are considered to 
have impaired awareness of hypoglycaemia, whereas those answering “often or always” are 
not. 
For Japan : 
• Inclusion crite ria 3 : age ≥ 20 years at the time of signing informed consent . 
• Preparation/Handling/Storage/Accountability : The head of the trial site or the trial 
product storage manager assigned by [CONTACT_111441] (a pharmacist in principle) is 
responsible for control and accountability of the trial products.  
• Trial governance consideration : A seal is accepted as signature.  
For Mexico:  
• Withdrawal from the trial:  should the subject, his/her family members, parents or legal 
representative decide to withdraw the  consent from the trial, the subject will be entitled to 
receive appropriate, free of charge medical care and/or trial drug during the follow -up period 
of the protocol when it will be established with certainty that no untoward medical 
consequences of the subject´s participation in the research occurred.  
 
• Trial governance considerations : In the case of Mexico, the following responsibilities will 
be included for the head of the Institution/Health Care Establishment, Ethics, Research and, 
when applicable, Bio safety Committees and sponsor within their scope of responsibility: a) 
Investigation follow -up; b) Damages to health arising from the investigation development; 
as well as those arising from interruption or advanced suspension of treatment due to non -
attributable reasons to the Subject; c) Timely compliance of the terms in which the 
authori sation of a research for health in human beings had been issued; d) To present in a 
timely manner the information required by [CONTACT_135534].  
 
• Indemnity statement:  a) Novo Nordisk carries product liability for its products, and 
liability as assumed under the special laws, acts/and/or guidelines for conducting clinical 
trials in any country, including those applicable provisions on the Mexican [LOCATION_002]. If 
the su bject feels that something goes wrong during the course of this trial, the subject should 
contact [CONTACT_215592].  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  84 of 94 
 
b) If during their participation in the trial the subject experiences a disease or injury that, 
according to the trial doctor and the sponsor, is directly caused by [CONTACT_135565]/or a study procedure that otherwise would not have been part of his/her regular medical 
care, the subject will receive from the institution or medical care establishment and free of 
charge, the appropriate medical treatment as required. In this case, the costs resulting from 
such treatment as well as the costs of any indemnification established by [CONTACT_881874]; 
even if the subject discontinues his/her participation in the study by [CONTACT_237209] a 
decision from the investigator.  
c) By [CONTACT_79844], the subject will not renounce to any compensation or 
indemnification he/she may be entitled to by [CONTACT_2371], nor will he/she will incur any additional 
expense as a result of his/her participation in the trial; any additional expense resulting from 
the subject’s participation in the trial will be covered by [CONTACT_135568].  
For Russia:  
• Trial governance considerations:  The trial should be conducted in compliance with the 
protocol, Ministry of Healthcare of Russian Federation’ order #200н from April, 01, 2016 
”Approval of rules of good clinical practice” and legal requirements of the Russ ian 
Federation regulating circulation of medicines.  
• BG meter and CGM:  The BG meter and CGM are not approved  at the time of the final 
protocol version 1.[ADDRESS_1233120] be reported to 
 on a special technical complaint paper form.  
Timelines for reporting, from the trial site obtaining knowledge of the technical complaint:  
o Technical complaint assessed as related to a SAE within [ADDRESS_1233121] 
vigilance procedures.  
CONFIDENTIAL

Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  85 of 94 
 
For Spain:  
• Retention of clinical trial documentation:  25 years according to the new Spanish Royal 
Decree 1090/2015.  
For Poland:  
• Indemnity statement:  Novo Nordisk carries liability for th e Trial exclusively in the scope 
defined by [CONTACT_684324] 6 September 2001 (uniform version Journal of Laws of 2008 No. 45 item 271 
with amendments). In order to support potential c laims for liability attributable to the Trial, 
Novo Nordisk and Investigator are covered by [CONTACT_111443].  
For [LOCATION_006] : 
• Screen failures : Minimal information includes informed consent date, demography, screen 
failure details,  eligibility criteria , and serious adverse event ( SAE ).   
 
• Discontinuation of trial treatment : Subjects that are randomised in violation of inclusion 
and exclusion criteria  should  be discontinued from the trial treatment.   
 
• Time period and  frequency for collecting AE and SAE information : All AEs and SAEs 
must be collected from the time of inform ed consent (V1) and until the end of trial visit as 
specified in the flowchart. For subjects discontinuing trial product prematurely SAEs must 
be co llected from the end of trial visit until the discontinuation follow -up 2 visit (V61A).  
 
Flowchart :  
 
• In-trial period : The subjects should  not be exposed to trial product if they are not 
randomised beforehand . 
 
For US:  
• Financial disclosure:  Verification  under disclosures per Code of Federal Regulations 
(CFR) of Financial Conflict of Interest.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  86 of 94 
 
For India  and Mexico  where CGM is not approved at the time of the final protocol  version 
1.0: 
• The CGM is regarded as an investigational device  and will be labelled to indicate f or 
investigational use only . The CGM has been selected in order to provide the best data 
accuracy and to be consistent in the global clinical programme .  
Technical complaints on the CGM must be reported to  on a special technical 
complaint paper form.  
Timelines for reporting, from the trial site obtaining knowledge of the technical complaint:  
o Technical complaint assessed as related to a SAE within [ADDRESS_1233122] vigilance procedures.  
CONFIDENTIAL

Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  87 of 94 
 
10.10  Appendix 10: Abbreviations  
AE adverse event  
ANCOVA  analysis of covariance  
BG blood glucose  
CGM  continuous glucose monitoring  
CI confidence interval  
CRF  case report form  
DPP-[ADDRESS_1233123]  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
GLP -1 RA glucagon -like peptide 1 receptor agonists  
HbA 1c glycated haemoglobin  
HCP  healthcare professional  
HRT  hormone replacement therapy  
IB investigator’s brochure  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IgE immunoglobulin E  
IMP investigational medicinal product  
INN international nonproprietary name  
[CONTACT_111447] -WOB  last available planned on -treatment without initiation of more than [ADDRESS_1233124]  
PCD  primary completion date  
PD pharmacodynamic  
PI [INVESTIGATOR_881854]:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233125] characteristics  
SMPG  self-measured plasma glucose  
T1D type 1 diabetes  mellitus  
T2D type 2 diabetes mellitus  
V visit 
WOCBP  woman of childbearing potential  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  89 of 94 
 
10.11  Appendix 11: Protocol amendment history  
The Protocol amendment summary of changes table for the current protocol version is located 
directly before the table of contents . 
Protocol version 3.0 (03 November 2020) , Italy only  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1. 
Overall rationale for preparing protocol, version 3.0:  
The protocol has been amended to meet local Italian requirement.    
Section # and name  [CONTACT_111444]  
5 Trial population  The sentence: “ For country specific 
requirement to the to the inclusion and 
exclusion criteria, please refer to 
Appendix 9 (Section 10.9) for further 
information. ” has been added.  To stress that country -specific 
requirements relevant for the 
eligibility criteria are described in 
appendix 9 . 
10.9 Appendix 9: Country -specific 
requirements  A new section describing Italian 
specific requirement has been added, 
in which three Italian specific 
addition al exclusion criteria are 
described.  To meet l ocal Italian  requirement . 
10.11  Appendix 11: Protocol 
amendment history  Description of the changes included in 
version 2.0 has been added (was 
former described in section “ Protocol 
amendment summary of changes  
table ”). Log amendments and version history . 
11 References  A reference has been added: “ Clarke 
WL, Cox DJ, Gonder -Frederick LA, 
Julian D, Schlundt D, Polonsky W. 
Reduced awareness of hypoglycemia 
in adults with IDDM. A prospective 
study of hypoglycemic f requency and 
associated symptoms. Diabetes Care. 
1995;18(4):517 -22”. Refence relevant for the added Italian 
exclusion criteria . 
 
Protocol version 2.0 ([ADDRESS_1233126] 2020) , [LOCATION_006] only  
This amendment is considered to be non -substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1, because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  90 of 94 
 
Overall rationale for preparing protocol, version 2.0:  
The protocol has been amended to meet local [LOCATION_006] requirement.  
Section  # and name  [CONTACT_111448] . Disclose version history  
5.4 Screen failures  The sentence: “For [LOCATION_006]: SAE is also 
included as minimal information” has 
been added at the end of  the first 
paragraph.  To meet local [LOCATION_006] requirement  
7.1 Discontinuation of trial treatment  The sentence ”not applicable for [LOCATION_006]” 
has been added at the end of the last 
sentence in the section.  To meet local [LOCATION_006] requirement  
8.3.[ADDRESS_1233127] 
paragraph: “For AE reporting in [LOCATION_006], 
please refer to the [LOCATION_006] specific 
requirements in Appendix 9 (Section 
10.9).”  To meet local [LOCATION_006] requirement  
9.3 Populations for analyses  The sentence ”not applicable for [LOCATION_006]” 
has been added after the sentence “For 
subjects not randomised but exposed 
to trial product the in -trial period 
starts at the date of first dose of tri al 
product”.  To meet local [LOCATION_006] requirement  
10.9 Appendix 9: Country -specific 
requirements  The following sentences has been 
added to the list of [LOCATION_006] specific 
requirements:  
“Screen failures : Minimal 
information includes informed 
consent date, demography, scr een 
failure details, eligibility criteria, and 
serious adverse event (SAE).”  
“Discontinuation of trial treatment: 
Subjects that are randomised in 
violation of inclusion and exclusion 
criteria  should be discontinued from 
the treatment”.  
“Time period and frequency for 
collecting AE and SAE information : 
All AEs and SAEs must be collected 
from the time of informed consent 
(V1) and until the end of trial visit as 
specified in the flowchart. For 
subjects discontinuing trial product 
prematurely SAEs must be col lected 
from the end of trial visit until the 
discontinuation follow -up 2 visit 
(V61A).”  To meet local [LOCATION_006] requirement  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November 2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  91 of 94 
 
Section  # and name  [CONTACT_111444]  
“In-trial period : The subjects should 
not be exposed to trial product if they 
are not randomised beforehand”.  
Further, a flowchart  disclosing [LOCATION_006] 
specific AE reporting h as been 
inserted.  
10.11 Appendix 11: Protocol 
amendment history  New appendix added . Log amendments and version history  
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November  2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  92 of 94 
 
11 References  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_1233128] of c linical trials on medicinal 
products for human use. 2001.  
2. American Diabetes Association. 2. Classification and Diagnosis of Diabetes:. Diabetes Care. 
2019;42(Suppl 1):S13 -S28. 
3. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. 2019.  
4. Alatorre C, Fernández Landó L, Yu M, Brown K, Montejano L, Juneau P, et al. Treatment 
patterns in patients with type 2 diabetes mellitus treated with glucagon -like peptide -1 
receptor agonists: Higher adherence and persistence with dulaglutide compared w ith once -
weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953 -61. 
5. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005;36(3):197 -209. 
6. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88 (4):787 -835, ix.  
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient -centred approach. 
Update to a position statement of the American Diabetes Association and the  European 
Association for the Study of Diabetes. Diabetologia. 2015;58(3):429 -42. 
8. European Medicines Agency. Guideline on clinical investigation of medicinal products in 
the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). 14 May 
2012.  
9. Halimi S, Balkau B. Better analyze the determinants of therapeutic inertia to overcome it. 
Diabetes Metab. 2012;[ADDRESS_1233129] 3:S27 -8. 
10. Khunti K, Millar -Jones D. Clinical inertia to insulin initiation and intensification in the [LOCATION_006]: 
A focused literat ure review. Prim Care Diabetes. 2017;11(1):3 -12. 
11. Novo Nordisk A/S. Investigator's Brochure, insulin icodec, project NN1436, (edition 6). 5 
Jun 2020.  
12. [COMPANY_011] -Aventis Deutschland GmbH. Lantus®  (insulin glargine), EU Summary of Product 
Characteristics  (SmPC). 2018.  
13. Food and Drug Administration. Lantus - U.S. Label information. 2015.  
14. [COMPANY_011] -Aventis Groupe. Lantus®  (insulin glargine), EU Summary of Product Characteristics 
(SmPC). [ADDRESS_1233130] J H. Patient perspectives on once -weekly 
medications for diabetes. Diabetes Obesity & Metabolism. 2011;13(2):144 -9. 
16. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease. http://www.kidney -international.org. 2 013. 
17. Food and Drug Administration, CDER. Guidance for Industry. Diabetes Mellitus: 
Developi[INVESTIGATOR_111391], Draft Guidance. 
February 2008.  
18. Russell -Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs 
insulin glargine and placebo in combination with metformin and sulfonylurea therapy in 
type 2 diabetes mellitus (LEAD -5 met+SU): a randomised controlled trial. Diabetologia. 
2009;52(10):2046 -55. 
19. Danne T, Nimri R, Battelino T, B ergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631 -40. 
20. Little R, Rubin D. Statistical analysis with missing data. Sons. JW, editor. [LOCATION_001].: John 
Wiley & Sons. 1 987. 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November  2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233131] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.  
22. ICH Harmonised Tripartite Guideline. Gui deline for Good Clinical Practice E6(R2),  Step 4 
version. 09 Nov 2016.  
23. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J  Med. 2004;351(12):[ADDRESS_1233132] of 2007 as amended by [CONTACT_43679] "Clinical 
Trials Registration and Results Information Submission". 2 1 September 2016.  
25. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medi cinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.  
26. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Cou ncil of 12 December 2006 on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. [ADDRESS_1233133], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at  www.icmje.org . 
28. Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report --
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol . 2006;117(2):391 -7. 
29. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin 
Immunol. 2002;110(3):341 -8. 
30. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised 
nomenclature for allergy for glob al use: Report of the Nomenclature Review Committee of 
the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832 -6. 
31. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL, et al. Potential seminal 
transport of pharmace uticals to the conceptus. Reprod Toxicol. 2015;58:213 -21. 
32. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 
mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of 
the American Diabetes Asso ciation and the European Association for the Study of Diabetes. 
Diabetes Care. 2017;40(1):155 -7. 
33. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in 
Diabetes -2018. Diabetes Care. 2018;41(Suppl 1):S55 -S64. 
34. Abraham MB, Jo nes TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD 
Clinical Practice Consensus Guidelines 2018: Assessment and management of 
hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;[ADDRESS_1233134] 
27:178 -92. 
35. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 
Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, 
the American As sociation of Diabetes Educators, the American Diabetes Association, the 
Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable 
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  30 November  2020  Novo Nordisk  
Trial ID: NN1436 -4477  Version:  4.0 
      Status:  Final  
      Page:  [ADDRESS_1233135], the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 
2017;40(12):[ADDRESS_1233136] ER, Anderson J, Childs B, Cryer P, Dagogo -Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384 -95. 
37. Clarke WL, Cox DJ, Gonder -Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517 -22. 
 
CONFIDENTIAL